

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02557 A1

- (51) International Patent Classification⁷: C12N 15/11, 15/12, C07K 14/71, C12Q 1/68, A61K 38/17, 48/00, G01N 33/50
- (74) Agent: BALDOCK, Sharon, Claire; Boulton Wade Tenant, Verulam Gardens, 70 Grays Inn Road, London WC1X 8BT (GB).
- (21) International Application Number: PCT/EP00/04918
- (22) International Filing Date: 26 May 2000 (26.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 9915200.1 29 June 1999 (29.06.1999) GB
- (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEUROTROPHIC FACTOR RECEPTOR



(57) Abstract: There is disclosed a mammalian receptor protein designated GFR α -4 and the nucleic acid sequence encoding therefor. Also provided is an expression vector comprising the nucleic acid sequence and host cells transformed or transfected with the vector. Host cells expressing the receptor may be used to identify agonists or antagonists in relation to the receptor.

- 1 -

NEUROTROPHIC FACTOR RECEPTOR

The present invention is concerned with cloning and expression of a novel mammalian receptor protein, designated herein GFR α -4 and in particular with an isolated nucleic acid sequence encoding the GFR α -4 protein, an expression vector comprising said nucleic acid sequence, a host cell transformed or transfected with said vector, isolated GFR α 4 protein, compounds which act as agonists or antagonists in relation to GFR α -4 and methods of identifying them, together with pharmaceutical compositions comprising the isolated nucleic acid, the receptor protein or said agonist or antagonist.

Neurotrophic growth factors are involved in neuronal differentiation, development and maintenance. These proteins can prevent degeneration and promote survival of different types of neuronal cells and are thus potential therapeutic agents for neurodegenerative diseases. Glial cell-line derived neurotrophic factor (GDNF) was the first member of a growing subfamily of neurotrophic factors structurally distinct from the neurotrophins. GDNF is a distantly related member of the transforming growth factor β (TGF- β) superfamily of growth factors, characterized by a specific pattern of seven highly conserved cysteine residues within the amino acid sequence (Kingsley, 1994). GDNF was originally purified using an assay based on its ability to maintain the survival and function of embryonic ventral midbrain dopaminergic neurons in vitro (Lin et al., 1993). Other neuronal cell types in the central (CNS) or peripheral nervous systems (PNS) have been shown to be responsive to the survival effects of GDNF (Henderson et al., 1994, Buj-Bello et al., 1995, Mount et al., 1995, Oppenheim et al., 1995). GDNF is produced by cells in an inactive

CONFIRMATION COPY

- 2 -

proform, which is cleaved specifically at a RXXR recognition site to produce active GDNF (Lin et al., 1993). In view of its effects on dopaminergic neurons, clinical trials have evaluated GDNF as a possible treatment for Parkinson's disease, a common neurodegenerative disorder characterized by the loss of a high percentage (up to 70 %) of dopaminergic cells in the substantia nigra of the brain. Exogenous administration of GDNF has potent protective effects in animal models of Parkinson's disease (Henderson et al., 1994, Beck et al., 1995, Tomac et al., 1995, Yan et al., 1995, Gash et al., 1996, Choi-Lundberg et al., 1997, Bilang-Bleuel et al., 1997, Mandel et al., 1997).

Recently, three new members of the GDNF family of neurotrophic factors have been discovered. Neurturin (NTN) was purified from conditioned medium from Chinese hamster ovary (CHO) cells using an assay based on the ability to promote the survival of sympathetic neurons in culture (Kotzbauer et al., 1996). The mature neurturin protein is 57% similar to mature GDNF. Persephin (PSP) was discovered by degenerate primer PCR using genomic DNA. The mature protein, like mature GDNF, promotes the survival of ventral midbrain dopaminergic neurons and of motor neurons in culture (Milbrandt et al., 1998). The similarity of the mature persephin protein with mature GDNF and neurturin is \approx 50 %. Very recently, a fourth member has been cloned using genomic DNA information in the public EMBL database and has been named Enovin (EVN) (Masure et al., 1999) or Artemin (ARTN) (Baloh et al., 1998b). This factor is \pm 57 % similar to NTN and PSP and acts primarily on peripheral neurons.

All four GDNF family members require a heterodimeric receptor complex in order to carry out downstream

- 3 -

intracellular signal transduction. GDNF binds to the GDNF family receptor alpha 1 (GFR α -1; also termed GDNFR α , RETL1 or TrnR1; GFR α Nomenclature Committee, 1997) subunit, a glycosyl phosphatidyl inositol (GPI)-
5 anchored membrane protein (Jing et al., 1996, Treanor et al., 1996, Sanicola et al., 1997). The GDNF/GFR α -1 complex subsequently binds to and activates the cRET proto-oncogene, a membrane bound tyrosine kinase (Durbec et al., 1996, Trupp et al., 1996), resulting
10 in phosphorylation of tyrosine residues in cRET and subsequent activation of downstream signal transduction pathways (Worby et al., 1996). GFR α -2 (also termed RETL2, NTNR- α , GDNFR- β or TrnR2), which is similar to GFR α -1, has been identified by a number
15 of different groups (Baloh et al., 1997, Sanicola et al., 1997, Klein et al., 1997, Buj-Bello et al., 1997, Suvanto et al., 1997). The human GFR α -1 and GFR α -2 receptor subunits are 49% identical and 63% similar by protein sequence with 30 of the 31 cysteine residues
20 conserved. Both receptors contain a hydrophobic domain at their carboxy-termini involved in GPI anchoring to the membrane. GFR α -1 and GFR α -2 are widely expressed in almost all tissues and expression may be developmentally regulated (Sanicola et al., 1997,
25 Widenfalk et al., 1997).

GFR α -1 is the preferred receptor for GDNF, whereas GFR α -2 preferentially binds neurturin (Jing et al., 1996, Treanor et al., 1996, Klein et al., 1997). It is
30 also clear, however, that there is some cross-talk between these growth factors and receptors as GDNF can bind to GFR α -2 in the presence of cRET (Sanicola et al., 1997) and neurturin can bind to GFR α -1 with low affinity (Klein et al., 1997). GDNF and neurturin are
35 thus part of a neurotrophic signalling system whereby different ligand-binding subunits (GFR α -1 and GFR α -2) can interact with the same tyrosine kinase subunit

- 4 -

(cRET).

Recently, a third member of the GFR α family of coreceptors, GFR α -3, has been described (Jing et al., 1997, Masure et al., 1998, Worby et al., 1998, Naveilhan et al., 1998, Baloh et al., 1998a). This receptor's amino acid sequence is 35% identical to both GFR α -1 and GFR α -2. GFR α -3 is not expressed in the developing or adult CNS, but is highly expressed in several developing and adult sensory and sympathetic ganglia of the PNS (Widenfalk et al., 1998, Naveilhan et al., 1998, Baloh et al., 1998a). GFR α -3 has been shown to be the preferred coreceptor for Enovin/artemin and also signals via cRET (Masure et al., 1999, Baloh et al., 1998b). Crosstalk between EVN/ARTN and GFR α -1 seems also possible, at least in vitro.

A fourth member of the GFR α family has been identified in chicken (Thompson et al., 1998) and has been shown to mediate signalling of persephin via cRET (Enokido et al., 1998). A functional mammalian homologue encoding a mammalian persephin receptor has yet to be discovered.

The present inventors have surprisingly identified a further novel mammalian receptor of the GDNF family designated herein as GFR α -4. The DNA sequence has been cloned and a number of splice variants encoding the receptor have also been identified.

Accordingly, there is provided by the present invention an isolated or substantially pure form of a nucleic acid encoding a mammalian GDNF family receptor α -4 designated GFR α -4. The nucleic acid molecule is preferably from rat, mouse or human. Preferably, the receptor encoded by said nucleic acid molecule

- 5 -

comprises the amino acid sequence illustrated in Sequence ID No's. 8 or 9 or encoding a functional equivalent, derivative or bioprecursor of said receptor.

5

Although initially, in view of the fact that only 4 members of the GFR α s were known, the new receptor has previously been called GFR α -5. However, it has now termed α -4 in order to comply with the existing nomenclature for GFR α family members and to indicate that the GFR α receptor of the present invention is the mammalian orthologue of the chicken GFR α -4 receptor.

Thus, the present invention relates to a nucleic acid molecule encoding a mammalian GDNF family receptor α -4 (GFR α -4) or an immunologically and/or biologically active fragment thereof, which comprises a nucleotide sequence selected from the group consisting of

- (a) nucleotide sequences encoding the polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 8 or 9;
- (b) nucleotide sequences comprising the coding sequence as depicted in SEQ ID NO: 5 or 6;
- (c) nucleotide sequences encoding a polypeptide derived from the polypeptide encoded by a nucleotide sequence of (a) or (b) by way of substitution, deletion and/or addition of one or several amino acids of the amino acid sequence encoded by the nucleotide sequence of (a) or (b);
- (d) nucleotide sequences the complementary strand of which hybridizes with a nucleotide sequence of any one of (a) to (c);
- (e) nucleotide sequences encoding a polypeptide the amino acid sequence of which has an identity of 30% or more to the amino acid sequence of the polypeptide encoded by a

- 6 -

- nucleotide sequence of any one of (a) to (d);
- 5 (f) nucleotide sequences encoding a polypeptide capable of binding persephin comprising a fragment or an epitope-bearing portion of a polypeptide encoded by a nucleotide sequence of any one of (a) to (e);
- 10 (g) nucleotide sequences comprising at least 15 consecutive nucleotides of a nucleotide sequence of any one of (a) to (f) and encoding a polypeptide capable of binding persephin; and
- 15 (h) nucleotide sequences comprising a nucleotide sequence which is degenerated as a result of the genetic code to a nucleotide sequence of any of (a) to (g).

Advantageously, the nucleic acid molecule according to the invention may be used for expression of said

20 GFR α -4 protein in, for example, a host cell or the like, using an appropriate expression vector. Preferably, the nucleic acid molecule is a DNA molecule, and even more preferably a cDNA molecule having a sequence as illustrated in any of Sequence ID

25 No's. 5 to 7 or the complement thereof. Alternatively, the nucleic acid molecule is capable of hybridising to the sequences of the invention under conditions of high stringency or to the complement thereof. Stringency of hybridisation as used herein

30 refers to conditions under which polynucleic acids are stable. The stability of hybrids is reflected in the melting temperature (T_m) of the hybrids. T_m can be approximated by the formula:

35
$$81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+] + 0.41 (\% \text{G\&C}) - 6001/1$$

- 7 -

wherein l is the length of the hybrids in nucleotides.
 T_m decreases approximately by 1-1.5°C with every 1% decrease in sequence homology.

5 The nucleic acid capable of hybridising to nucleic acid molecules according to the invention will generally be at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the nucleotide sequences according to the invention.

10 Advantageously, the antisense molecule may be used as a probe or as a medicament or in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient.

15 According to a second aspect of the invention, there is provided a DNA expression vector comprising the DNA molecule according to the invention. This vector may, advantageously, be used to transform or transfect a
20 host cell to achieve expression of GFR α -4 according to the invention. Preferably, the DNA is included in a plasmid, for subsequent transfection or transformation of the host cell.

25 An expression vector according to the invention includes a vector having a nucleic acid according to the invention operably linked to regulatory sequences, such as promoter regions, that are capable of effecting expression of said DNA fragments. The term
30 "operably linked" refers to a juxta position wherein the components described are in a relationship permitting them to function in their intended manner. Such vectors may be transformed into a suitable host cell to provide for expression of a polypeptide
35 according to the invention. Thus, in a further aspect, the invention provides a process for preparing receptors according to the invention which comprises

- 8 -

5 cultivating a host cell, transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the receptors, and recovering the expressed receptors.

10 The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of said nucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable markers, such as, for example, ampicillin resistance.

15 Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector may include a promoter such as the lac promoter and for transcription initiation in the Shine-Dalgarno
20 sequence and the start codon AUG. Similarly, a eukaryotic expression vector may include a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of
25 the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art.

30 Nucleic acid molecules according to the invention may be inserted into the vectors described in an antisense orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense nucleic acids may be produced by synthetic means.

35 In accordance with the present invention, a defined nucleic acid includes not only the identical nucleic acid but also any amino base variations including, in

- 9 -

particular, substitutions in bases which result in a synonymous codon (a different codon specifying the same amino acid residue) due to the degenerate code in conservative amino acid substitutions. The term
5 "nucleic acid sequence" also includes the complementary sequence to any single stranded sequence given regarding base variations.

10 The present invention also advantageously provides nucleic acid sequences of at least approximately 10 contiguous nucleotides of a nucleic acid according to the invention and preferably from 10 to 50 nucleotides. These sequences may, advantageously, be
15 used as probes or primers to initiate replication, or the like. Such nucleic acid sequences may be produced according to techniques well known in the art, such as, by recombinant or synthetic means. They may also be used in diagnostic kits or the like for detecting the presence of a nucleic acid according to the
20 invention. These tests generally comprise contacting the probe with the sample under hybridising conditions and detecting for the presence of any duplex or triplex formation between the probe and any nucleic acid in the sample.

25 According to the present invention these probes may be anchored to a solid support. Preferably, they are present on an array so that multiple probes can simultaneously hybridize to a single biological
30 sample. The probes can be spotted onto the array or synthesised *in situ* on the array. (See Lockhart et al., Nature Biotechnology, vol. 14, December 1996 "Expression monitoring by hybridisation into high density oligonucleotide arrays". A single array can
35 contain more than 100, 500 or even 1,000 different probes in discrete locations.

The nucleic acid sequences, according to the invention may be produced using such recombinant or synthetic means, such as, for example, using PCR cloning mechanisms which generally involve making a pair of
5 primers, which may be from approximately 10 to 50 nucleotides to a region of the gene which is desired to be cloned, bringing the primers into contact with mRNA, cDNA, or genomic DNA from a human cell, performing a polymerase chain reaction under
10 conditions which bring about amplification of the desired region, isolating the amplified region or fragment and recovering the amplified DNA. Generally, such techniques as defined herein are well known in the art, such as described in Sambrook et al
15 (Molecular Cloning: a Laboratory Manual, 1989).

The nucleic acids or oligonucleotides according to the invention may carry a revealing label. Suitable labels include radioisotopes such as ^{32}P or ^{35}S , enzyme
20 labels or other protein labels such as biotin or fluorescent markers. Such labels may be added to the nucleic acids or oligonucleotides of the invention and may be detected using known techniques *per se*.

25 The present invention also comprises within its scope proteins or polypeptides encoded by the nucleic acid molecules according to the invention or a functional equivalent, derivative or bioprecursor thereof. Preferably, the protein comprises the amino acid
30 sequence of Sequence ID No's. 8 and 9.

A "functional equivalent" as defined herein should be taken to mean a receptor that exhibits the same properties and functionality associated with the
35 GFR α -4 receptor according to the invention. A "derivative" should be taken to mean a polypeptide or protein in which certain amino acids may have been

- 11 -

altered or deleted or replaced and which polypeptide or protein retains biological activity of said GFR α -4 receptor and/or which can cross react with antibodies raised using a receptor according to the invention as the challenging antigen.

Encompassed within the scope of the invention are hybrid and modified forms of the GFR α -4 receptor according to the invention including fusion proteins and fragments. The hybrid and modified forms include, for example, when certain amino acids have been subjected to some modification or replacement, such as for example, by point mutation and yet which results in a protein which possesses the same receptor specificity as the GFR α -4 receptor of the invention.

In this context it is understood that the terms biological activity, receptor specificity and functional receptor (fragment) preferably include the ability to bind persephin, preferably specifically and that the GFR α -4 of the invention has no or substantially no binding activity on GDNF, NTN, and/or EVN/ART. The biological activity, receptor specificity and/or functionality, for example binding activity of the GFR α -4 of the invention, variants, derivatives and fragments thereof can be determined according methods well known in the art, preferably as described in the appended examples. Preferably, the K_D of the GFR α -4 of the invention for persephin is 1 to 10×10^{-9} , particularly preferred $5.9 \pm 2.8 \times 10^{-9}$ when determined in accordance with the examples described below; see the description to Table 6.

The protein according to the invention should be taken to include all possible amino acid variants encoded by the nucleic acid molecule according to the invention

- 12 -

including a polypeptide encoded by said molecule and having conservative amino acid changes. Proteins or polypeptides according to the invention further include variants of such sequences, including
5 naturally occurring allelic variants which are substantially homologous to said proteins or polypeptides. In this context, substantial homology is regarded as a sequence which has at least 70%, and preferably 80 or 90% amino acid homology with the
10 proteins or polypeptides encoded by the nucleic acid molecules according to the invention.

Substantial homology should be taken to mean that the nucleotide and amino acid sequences of the GFR α -4 of
15 the invention display a certain degree of sequence identity. Preferably they share an identity of at least 30 %, preferably 40 %, more preferably 50 %, still more preferably 60 %, most preferably 70%, and particularly an identity of at least 80 %, preferably
20 more than 90 % and still more preferably more than 95 % is desired with respect to the nucleotide or amino acid sequences depicted in Seq. ID Nos. 5 to 9, respectively. A preferred method for determining the best overall match between a query sequence (a
25 sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using, for example, the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6 (1990), 237-245.)
30 In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Further programs that can be used in order to
35 determine homology/identity are described below and in the examples. The sequences that are homologous to the sequences described above are, for example, variations

- 13 -

of said sequences which represent modifications having the same biological function, in particular encoding proteins with the same or substantially the same receptor specificity, i.e. binding specificity. They may be naturally occurring variations, such as sequences from other mammals, or mutations. These mutations may occur naturally or may be obtained by mutagenesis techniques. The allelic variations may be naturally occurring allelic variants as well as synthetically produced or genetically engineered variants. In a preferred embodiment the sequences are derived from mouse, more preferable from human. These sequences can also be retrieved from existing databases with nucleotide sequences of yet unknown function. For example, a BLAST search on the EMBL database using the identified rat GFR α -4 sequences as query sequence yielded a genomic mouse sequence (accession no. AF155960) and a genomic human sequence (accession no. AC017113; containing contigs. derived from human genomic DNA) with parts almost identical with parts of the rat GFR α -4 sequence (exons 2, 3 and 4). These nucleotides sequences are also encompassed in the present invention.

A further aspect of the invention comprises the host cell itself transformed with the DNA expression vector described herein, which host cell preferably comprises a eukaryotic cell, which may be for example, a mammalian cell, an insect cell or yeast cell or the like. In one embodiment the cell comprises a human embryonic kidney cell and preferably a cell of the HEK293 cell line. Alternatively, the cell may comprise NIH/3T3 mouse fibroblasts or Chinese hamster ovary (CHO) cells or COS-7 cells.

Further provided by the present invention is a transgenic cell, tissue or organism comprising a

transgene capable of expressing GFR α -4 according to the invention, or of expressing a functional equivalent, derivative or bioprecursor of said receptor. The term "transgene capable of expression" as used herein means a suitable nucleic acid sequence which leads to expression of a human receptor having the same function and/or activity as GFR α -4. The transgene may include, for example, genomic nucleic acid isolated from rat cells or synthetic nucleic acid, including cDNA, integrated into the genome or in an extra chromosomal state. Preferably, the transgene comprises the nucleic acid sequence encoding GFR α -4 according to the invention or a functional fragment of said nucleic acid. A functional fragment of said nucleic acid should be taken to mean a fragment of the gene or cDNA encoding GFR α -4 receptor or a functional equivalent or bioprecursor of said GFR α -4 which fragment is capable of being expressed to produce a functional receptor protein. For example, the gene may comprise deletions or mutations but may still encode a functional receptor.

Further provided by the present invention is an isolated or purified GFR α -4 protein having the amino acid sequence illustrated in Sequence ID No. 2 or a functional fragment or bioprecursor of said receptor or alternatively a GFR α -4 protein expressed by the transgenic cell, tissue or organism according to the invention. Also provided by the invention are membrane preparations from cells expressing GFR α -4.

The present invention is further directed to inhibiting GFR α -4 *in vivo* by the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA.

- 15 -

For example, the 5' coding portion of the mature protein sequence, which encodes for the protein of the present invention, is used to design an antisense RNA oligonucleotide of from 10 to 40 base pairs in length.

5 A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple-helix - see Lee et al. Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991), thereby

10 preventing transcription and the production of GFR α -4. The antisense RNA oligonucleotide hybridises to the mRNA *in vivo* and blocks translation of an mRNA molecule into the GFR α -4 receptor.

15 Antibodies to the GFR α -4 receptor according to the invention are also provided which may be used in a medicament or in a pharmaceutical composition.

20 Antibodies to the GFR α -4 of the invention may, advantageously, be prepared by techniques which are known in the art. For example, polyclonal antibodies may be prepared by inoculating a host animal, such as a mouse, with the polypeptide according to the invention or an epitope thereof and recovering immune

25 serum. Monoclonal antibodies may be prepared according to known techniques such as described by Kohler R. and Milstein C., Nature (1975) 256, 495-497.

30 Antibodies according to the invention may also be used in a method of detecting for the presence of GFR α -4 by reacting the antibody with a sample and identifying any protein bound thereto. A kit may also be provided for performing said method which comprises an antibody according to the invention and means for reacting the

35 antibody with said sample.

- 16 -

- Advantageously, the antibody according to the invention may also be used as a medicament or in the preparation of a medicament for treating diseases associated with expression of the GFR α -4 of the invention. The invention also further provides a pharmaceutical composition comprising said antibody together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
- 10 Proteins which interact with the polypeptide of the invention may be identified by investigating protein-protein interactions using the two-hybrid vector system first proposed by Chien et al (1991), Proc. Natl. Acad. Sci. USA 88 : 9578-9582.
- 15 This technique is based on functional reconstitution *in vivo* of a transcription factor which activates a reporter gene. More particularly the technique comprises providing an appropriate host cell with a
- 20 DNA construct comprising a reporter gene under the control of a promoter regulated by a transcription factor having a DNA binding domain and an activating domain, expressing in the host cell a first hybrid DNA sequence encoding a first fusion of a fragment or all
- 25 of a nucleic acid sequence according to the invention and either said DNA binding domain or said activating domain of the transcription factor, expressing in the host at least one second hybrid DNA sequence, such as, a library or the like, encoding putative binding
- 30 proteins to be investigated together with the DNA binding or activating domain of the transcription factor which is not incorporated in the first fusion; detecting any binding of the proteins to be investigated with a protein according to the invention
- 35 by detecting for the presence of any reporter gene product in the host cell; optionally isolating second hybrid DNA sequences encoding the binding protein.

- 17 -

Proteins which bind to the GFR α -4 receptor can be identified using this technique. The proteins identified can also be used to identify compounds which acts as agonists/antagonists of these proteins.

5 The structure of the receptor can also be used to design agonists or antagonists of the receptor. The present invention also comprises an agonist or antagonist of the human GFR α -4 receptor according to the invention which agonist or antagonist

10 advantageously may also be used as a medicament or in a pharmaceutical composition together with a pharmaceutically acceptable carrier diluent or excipient therefor.

15 Agonists or antagonists may be identified by contacting a cell expressing GFR α -4 with a compound to be tested and monitoring the degree of any GFR α -4 mediated functional or biological response, such as for example, by monitoring the level of

20 phosphorylation in said cell or by cytosensor or ligand binding assays in the presence of cRET or similar proteins in the signal transduction pathway. Preferably, the cell may be a host cell or transgenic cell according to the invention as defined herein.

25 Agonists and antagonists of GFR α -4 may also be identified by, for example, contacting a membrane preparation comprising GFR α -4 with the compound to be tested in the presence of cRET or other similar proteins involved in the signal transduction pathway

30 of which GFR α -4 is a component and monitoring the interaction of GFR α -4 with cRET or said similar proteins. Advantageously, any compounds or molecules identified as agonists or antagonists in relation to GFR α -4 may themselves be used in a pharmaceutical

35 composition as defined above or as a medicament.

- 18 -

Also provided by the invention are molecules or compounds that act on the signal transduction pathway of which GFR α -4 or a functional equivalent belong. Alternatively, the molecules may interfere with
5 complex formation or interaction of GFR α -4 or its functional equivalent, with cRET or a similar protein in the signal transduction pathway of which GFR α -4 is a component.

10 Furthermore, the present invention relates to a method of producing an antagonist or agonist of GFR α -4 according to the invention comprising the steps of any one of the above described screening methods; and additionally

15 (i) synthesizing the compound obtained or identified in said method or an physiologically acceptable analog or derivative thereof in an amount sufficient to provide said antagonist or agonist in a
20 therapeutically effective amount to a patient; and/or

(ii) combining the compound obtained or identified in said method or an analog or derivative thereof with a pharmaceutically
25 acceptable carrier".

The compounds isolated by the above methods also serve as lead compounds for the development of analog compounds. The analogs should have a stabilized
30 electronic configuration and molecular conformation that allows key functional groups to be presented to the GFR α -4 receptor in substantially the same way as the lead compound. In particular, the analog compounds have spatial electronic properties which are
35 comparable to the binding region, but can be smaller molecules than the lead compound, frequently having a molecular weight below about 2 kD and preferably below

- 19 -

about 1 kD. Identification of analog compounds can be performed through use of techniques such as self-consistent field (SCF) analysis, configuration interaction (CI) analysis, and normal mode dynamics analysis. Computer programs for implementing these techniques are available; e.g., Rein, Computer-Assisted Modeling of Receptor-Ligand Interactions (Alan Liss, New York, 1989). Methods for the preparation of chemical derivatives and analogues are well known to those skilled in the art and are described in, for example, Beilstein, Handbook of Organic Chemistry, Springer edition New York Inc., 175 Fifth Avenue, New York, N.Y. 10010 U.S.A. and Organic Synthesis, Wiley, New York, USA. Furthermore, said derivatives and analogues can be tested for their effects according to methods known in the art; see also supra. Furthermore, peptidomimetics and/or computer aided design of appropriate derivatives and analogues can be used.

Compounds identified as agonists or antagonists in relation to GFR α -4 or as ligands or compounds which interfere with the signal transduction pathway of which GFR α -4 is a part, may advantageously be used in the preparation of a medicament for treatment of neurodegenerative diseases, such as, for example, Alzheimers disease, Parkinsons disease, Motor Neuron Disease, peripheral neuropathy, spinal cord injury, familial hirschsprung disease, in addition to various carcinomas such as for example in gastrointestinal cancer and also in treatment of diseases which may be associated with GFR α -4 dysfunction. Compounds identified as antagonists may, advantageously, be used in the preparation of a medicament for the treatment of carcinoma or in alleviating pain.

- 20 -

The present invention also further comprises a method of identifying ligands of GFR α -4 according to the invention, which method comprises contacting said receptor with either a cell extract or alternatively a
5 compound to be tested for its potential as a GFR α -4 ligand, and isolating any molecules bound to GFR α -4.

A diagnostic kit is also provided by the present invention, which kit, comprises a probe including any
10 of, a nucleic acid molecule encoding a GFR α -4 protein according to the invention, a molecule capable of hybridising thereto under high stringency conditions, a fragment of said nucleic acids, an antisense molecule according to the invention, together with
15 means for contacting biological material to be tested with said nucleic acid probe. A diagnostic kit in accordance with the invention may also comprise an agonist or antagonist in relation to GFR α -4 or an antibody, preferably a monoclonal antibody to GFR α -4.
20 Thus, advantageously, the kit may be used, as appropriate to identify, for example, cells expressing or lacking in said receptor or genetic defects or the like or for determining whether a compound is a agonist or an antagonist of GFR α -4 receptor. Kits for
25 determining whether a compound is an agonist or an antagonist in relation to GFR α -4 may comprise a cell or membrane preparation expressing said receptor according to the present invention, means for contacting said cell with said compound and means for
30 monitoring the level of any GFR α -4 mediated functional or biological response, by for example measuring the level of phosphorylation in said cell or by cytosensor or ligand binding assays in the presence of cRET or similar proteins involved in the signal transduction
35 pathway of which GFR α -4 is a component.

- 21 -

The present invention may be more clearly understood from the following exemplary embodiment with reference to the accompanying figures wherein;

5 Figure 1: is an illustration of the Structure of the rat GFR α -4 gene. The top line shows a scale in bp. The line below shows the genomic structure of the rat GFR α -4 gene. Exons are represented by boxes and
10 numbered, intron sequences are depicted as lines. The sizes (in bp) of introns and exons are indicated above the diagram. The translation start codon is indicated by an arrow and the stop codon by an asterisk. The cDNA sequences of variants A and B obtained by
15 splicing out the intron sequences is shown below the genomic sequence. Alternative splicing of intron 5 results in an earlier stop codon in splice variant B. The predicted protein sequences of variants A and B are shown at the bottom. The predicted signal peptide, a putative N-glycosylation site and a hydrophobic
20 COOH-terminal region preceded by one or two possible sites for GPI-cleavage (in variant A only) are indicated on the diagrams.

25 Figure 2: is an alignment of the predicted protein sequences of splice variants A and B of rat GFR α -4. The sequences of rat GFR α -4 splice variants A and B were aligned using the ClustalW alignment program (EMBL, Heidelberg, Germany). Amino acid residues conserved between the 2 variants are included in the
30 black areas. Amino acid residues are numbered to the right. The dashes indicate gaps introduced into the sequence to optimize the alignment.

35 Figure 3: is an alignment of the predicted protein sequences of GFR α family members. The sequence of rat GFR α -4 variants A and B, rat GFR α -1 (EMBL acc. no. U59486), rat GFR α -2 (EMBL acc. no. AF003825), mouse

- 22 -

GFR α -3 (EMBL acc. no. AB008833) and chicken GFR α -4 (EMBL acc. no. AF045162) were aligned using the ClustalW alignment program (EMBL, Heidelberg, Germany). Amino acid residues conserved between all 6 proteins are included in the black areas. Residues conserved between 4 or 5 of the sequences are shaded in grey. Cysteine residues conserved between all six GFR α 's are indicated with an asterisk above the sequence. Amino acid residues are numbered to the right. The dashes indicate gaps introduced into the sequence to optimize the alignment.

Figure 4: Northern blot analysis of rodent GFR α -4 mRNA expression. The expression of rat and mouse GFR α -4 mRNA in different tissues was assessed using a probe corresponding to the coding sequence of rat GFR α -4 to analyze blots of poly(A)-rich RNA. (A) Rat Multiple Tissue Northern (MTN) blot; (B) Mouse MTN blot and (C) Mouse Embryo MTN blot. Apparent sizes are indicated (in kilobase pairs) by horizontal lines to the left of each panel.

Figure 5. The rat GFR α -4 gene is localized on chromosome 3q36. A mixture of two rat GFR α -4 probes was used for FISH analysis. (A) Double-spot FISH signals on the middle-distal part of rat chromosome 3 (arrows). (B) Position of the GFR α -4 gene locus on rat chromosome 3q36.

30 Oligonucleotide synthesis for PCR and DNA sequencing.

All oligonucleotide primers used were ordered from Eurogentec (Seraing, Belgium). Insert-specific sequencing primers (15- and 16-mers) and primers for use in PCR reactions were designed manually. DNA was prepared on Qiagen-tip-20 or -100 anion exchange or Qiaquick spin columns (Qiagen GmbH, Düsseldorf,

- 23 -

Germany) and recovered from the columns in 30 μ l TE-buffer (10 mM Tris.HCl, 1 mM EDTA (sodium salt), pH 8.0). Sequencing reactions were done on both strands using the ABI prism BigDye Terminator Cycle sequencing kit and were run on an Applied Biosystems 377XL sequencer (Perkin Elmer, ABI Division, Foster City, CA, USA). The Sequencher™ software was used for sequence assembly and manual editing (GeneCodes, AnnArbor, MI, USA).

Identification of a cDNA sequence encoding a novel member of the GFR α family

Using the human GFR α -1, GFR α -2 or GFR α -3 DNA or protein sequences as the query sequence, BLAST (Basic Local Alignment Search Tool; Altschul et al., 1990) searches were performed on the daily updates of the public EMBL database. A mouse EST (expressed sequence tag) sequence with EMBL accession number AU035938 showed homology to GFR α -1, GFR α -2 and GFR α -3. The smallest sum probabilities (SSP) obtained by the BLAST analyses are summarized in Table 1.

Table 1: BLAST results.

Query sequence	DNA/PROTEIN	SSP
GFR α -1	protein	7.5e-25
GFR α -2	protein	1.3e-12
GFR α -3	protein	2.2e-20
GFR α -1	DNA	6.6e-09
GFR α -2	DNA	>0.011
GFR α -3	DNA	0.0096

AU035938 (sequence 1) is a sequence of 792 bp derived from a mouse brain cDNA library. To obtain consistent homology with other members of the GFR α family upon translation a frame shift has to be introduced near position 165 in the DNA sequence. It is not clear whether this is due to a sequencing error or whether there is another explanation. Using this EST sequence

- 24 -

as the query sequence, the BLAST search against the public EMBL database was repeated. One additional clone (acc. no. AA823200; sequence 2) yielded a significant SSP of $1e-18$. Upon inspection of this 497 bp clone, which was derived from a mouse mammary gland cDNA library, only the first 61 bp were identical with part of AU035938 (position 353 to 415). The rest of the sequence of AA823200 was different from AU035938, but contained parts of which the translated amino acid sequence showed homology with the other GFR α 's. Therefore it was hypothesized that AU035938 and AA823200 could represent two variant forms of the same receptor, which was called GFR α -4.

Cloning of mouse GFR α -4 cDNA

First, we tried to amplify a fragment of the mouse GFR α -4 cDNA on Marathon ReadyTM cDNAs (Clontech Laboratories, Palo Alto, CA, USA) derived from mouse brain and mouse embryo. Primers were designed using the EST sequences (EMBL acc. no. AU035938 and AA823200) to amplify a 274 bp fragment of mouse GFR α -4. The primers used for the amplification of mouse GFR α -4 are shown in the table below.

Table 2: Primers used for the amplification of mouse GFR α -4 DNA sequences.

Name	Sequence	n
MOUSE-GFR α 4-sp2	CGCGTTGTCTGCGGTCTACG	21
MOUSE-GFR α 4-sp3	CGGCGGAAGAATGCGAAGC	20
MOUSE-GFR α 4-ap2	CACCCACGTACCATGGCATGTGC	23

PCR reactions were done using the Taq polymerase system (Boehringer Mannheim, Mannheim, Germany). PCR reactions were performed in a total volume of 50 μ l, containing 1x Taq PCR reaction buffer, 0.25 mM dNTP,

- 25 -

0.5 μ M of primers MOUSE-GFR α 4-sp2 and MOUSE-GFR α 4-ap2, 1 μ l of Taq polymerase and 2 μ l of mouse embryo or mouse brain Marathon Ready™ cDNA. Samples were heated to 95°C for 5 min and cycling was done for 30 s at 94°C, 1 min at 60°C and 45 s at 72°C for 35 cycles, with a final step of 7 min at 72°C. A semi-nested PCR was then performed on 1 μ l of the primary PCR reaction with primers MOUSE-GFR α 4-sp3 and MOUSE-GFR α 4-ap2. PCR reactions were performed in a total volume of 50 μ l, containing 1x Taq PCR reaction buffer, 0.25 mM dNTP, 0.5 μ M of primers MOUSE-GFR α 4-sp3 and MOUSE-GFR α 4-ap2, 1 μ l of Taq polymerase and 1 μ l of primary PCR product. Samples were heated to 95°C for 5 min and cycling was done for 30 s at 94°C, 1 min at 60°C and 45 s at 72°C for 35 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% (w/v) agarose gel in 1x TAE buffer (40 mM Tris-acetate, 1 mM EDTA (sodium salt), pH 8.3). A PCR fragment of the expected size (270 bp) was excised from the gel and purified with the Qiaquick gel extraction kit (Qiagen GmbH, Hilden, Germany). The PCR fragments were sequenced to confirm their identity. The obtained sequence corresponded to the EST database sequences. In order to determine the upstream and downstream coding sequences of mouse GFR α -4, 5' and 3' RACE experiments were performed. Since these experiments did not work as expected and since, at some points, frame shifts had to be introduced in the mouse GFR α -4 sequence to yield consistent homology with other GFR α 's after translation, we decided to shift to the cloning of the rat homologue of mouse GFR α -4.

Identification and cloning of rat GFR α -4 cDNA sequences

- 26 -

The cDNA sequences with accession number AU035938 and AA823200 described above were used as the query sequence in BLAST searches on the proprietary LifeSeq and ZooSeq databases (Incyte Pharmaceuticals, Palo Alto, CA, USA). Two rat clones with high homology to the mouse GFR α -4 sequences were identified: number 701290919H1 (270 bp; hit with AU035938 (SSP = 1.1e-32) and with AA823200 (SSP = 1.3e-21)) and number 701291473H1 (250 bp; hit only with AA823200 (SSP = 4.3e-42)). From comparing the translated protein sequences derived from clones 701291473H1 and 701290919H1 to the known GFR α protein sequences, it could be deduced that sequence 701290919H1 was probably localised 5' to sequence 701291473H1 and that these sequences were almost adjacent to each other in the full GFR α -4 cDNA sequence. Therefore, two forward primers (RAT-GFR α 4-sp1 and RAT-GFR α 4-sp2) were designed in the 5' region of sequence 701290919H1 and two reverse primers (RAT-GFR α 4-ap1 and RAT-GFR α 4-ap2) in the 3' region of sequence 701291473H1. All primer sequences used in PCR experiments are summarized in Table 3.

25

- 27 -

Table 3: Primers used for the amplification of rat GFR α -4 sequences. The RACE-ap1 and RACE-ap2 primers are included in the Marathon Ready™ cDNA kit.

5

10

15

20

25

Name	Sequence	n
RAT-GFR α 4-sp1	GTGGTCACCCCCAACTACCTGG	22
RAT-GFR α 4-sp2	GCCTTCCGCAAGCTTTTACAAGG	24
RAT-GFR α 4-sp3	GCTCTTCTGCGGATGCGAAGGC	22
RAT-GFR α 4-sp4	AGCTGCCGGGTTTACTGATGCTAC	24
RAT-GFR α 4-sp5	GATGCTACTCTCCCAAGGTCAGGC	24
RAT-GFR α 4-sp6	CTGGTAAGCTTTAAGGCAGAGGAGACC	27
RAT-GFR α 4-ap1	CATGGCAGTCAGCTGTGTTGTCC	23
RAT-GFR α 4-ap2	CAGCTGTGTTGTCCATGGTTCACC	24
RAT-GFR α 4-ap3	TGGTTGCGAGCTGTCAAAGGCTTGTATGGC	30
RAT-GFR α 4-ap4	GGGGTTCCTTGTA AAAAGCTTGCGGAAGGC	30
RAT-GFR α 4-ap5	GGTCCAAGGGCTTCAGGCAGGAAGG	25
RAT-GFR α 4-ap6	GCCTTCGCATCCGCAGAAGAGC	22
RAT-GFR α 4-ap7	CCAGGTAGTTGGGGGTGACCACG	23
RAT-GFR α 4-ap7b	CCCAGGCATTGCGCCACGTA	20
RAT-GFR α 4-ap8	CATTGCGCCACGTACTCGGAGC	22
RAT-GFR α 4-ap9	GACCTGAGGGCAAGGGAGTTTCA	23
RAT-GFR α 4-ap10	GCAAGGGAGTTTCAGTTCAGTGAGC	25
RACE-ap1	CCATCCTAATACGACTCACTATAGGGC	27
RACE-ap2	ACTCACTATAGGGCTCGAGCGGC	23

A PCR was then performed using primers RAT-GFR α 4-sp1 and RAT-GFR α 4-ap1 on rat brain Quickclone cDNA (Clontech Laboratories, Palo Alto, CA, USA) to confirm the presence of rat GFR α -4 in brain-derived cDNA. Since the DNA sequence coding for the rat GFR α -4 sequence has a high G+C content in this region, PCR reactions were done using the Advantage-GC PCR kit (Clontech). PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFR α 4-sp1 and RAT-GFR α 4-ap1, 1 μ l of Advantage KlenTaq polymerase mix and 1 μ l of rat brain Quickclone cDNA. Samples were heated to 95°C for 1 min and cycling was done for 1 min at 95°C, 1 min at 56°C

40

- 28 -

and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. A nested PCR was then performed on 1 µl of the primary PCR reaction with primers RAT-GFRα4-sp2 and RAT-GFRα4-ap2. PCR reactions were performed in a total volume of 50 µl, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFRα4-sp2 and RAT-GFRα4-ap2, 1 µl of Advantage KlenTaq polymerase mix and 1 µl of primary PCR product. Samples were heated to 95°C for 1 min and cycling was done for 30 s at 95°C, 1 min at 56°C and 1 min at 72°C for 25 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% (w/v) agarose gel in 1x TAE buffer (40 mM Tris-acetate, 1 mM EDTA (sodium salt), pH 8.3). Two PCR fragments of approximately 1100 and 200 bp, respectively, were excised from the gel and purified with the Qiaquick gel extraction kit (Qiagen GmbH, Hilden, Germany). The PCR fragments were sequenced to confirm their identity. The smallest fragment yielded a sequence of 211 bp corresponding to the joined sequences 701290919H1 and 701291473H1. The larger fragment yielded a sequence of 1049 bp of which 18 bp at the 5' end, 59 bp at the 3' end and an internal stretch of 92 bp corresponded to the sequence of the 211 bp fragment, but which had additional sequence stretches in between. This fragment represented a variant of rat GFRα-4.

Both clones 701291919H1 and 701291473H1 were obtained from Incyte Pharmaceuticals and the inserts completely sequenced. The sequences are included in this application (sequence 3 = 701290919H1 and sequence 4 = 701291473H1). Both clones were derived from the same 7-day old rat brain cortex cDNA library. Both clones

- 29 -

differ in their 5' ends (first 134 bp in 701291473H1 and first 227 bp in 701290919H1) but are identical thereafter. Both contain part of the GFR α -4 coding sequence up to a stop codon (position 184-186 in 701291473H1 and 277-279 in 701290919H1). A 3' untranslated region of 549 bp followed by a poly(A)-tail is then present in both clones. We hypothesized that both clones are different variants of the rat GFR α -4 gene. Primers (RAT-GFR α 4-ap3 and RAT-GFR α 4-ap4) were designed on a part of the sequence common to both variants to perform 5' RACE experiments in order to determine the 5' end of the rat GFR α -4 cDNA.

First, a 5' RACE PCR was performed on rat brain Marathon Ready™ cDNA (Clontech). PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M or 1.5 M GC-MELTä, 200 nM of primers RAT-GFR α 4-ap3 and RACE-ap1, 1 μ l of Advantage KlenTaq polymerase mix and 5 μ l of rat brain Marathon Ready™ cDNA. Samples were heated to 95°C for 30 s and cycling was done for 30 s at 95°C, 4 min at 72°C for 5 cycles, then 30 s at 95°C, 4 min at 70°C for 5 cycles, then 30 s at 95°C, 4 min at 68°C for 25 cycles, with a final step of 7 min at 68°C. A nested PCR was then performed on 1 μ l of the primary PCR reaction with primers RAT-GFR α 4-ap4 and RACE-ap2. PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M or 1.5 M GC-MELTä, 200 nM of primers RAT-GFR α 4-ap4 and RACE-ap2, 1 μ l of Advantage KlenTaq polymerase mix and 1 μ l of primary PCR product. Cycling was done using exactly the same parameters as for the primary PCR. PCR products were analysed on a 1% (w/v) agarose gel in 1x TAE buffer (40 mM Tris-acetate, 1 mM EDTA (sodium salt), pH 8.3).

- 30 -

A fragment of approximately 350 bp was excised from the gel and cloned into the plasmid vector pCR2.1-TOPO using the TOPO TA cloning kit according to manufacturer's instructions (Invitrogen BV, Leek, The Netherlands). One of the resulting clones yielded an insert sequence of 387 bp which extended the rat GFR α -4 sequence in the 5' direction. Upon translation, this additional cDNA sequence yielded a protein sequence without any internal stop codons and with substantial homology to the other known GFR α sequences. Since no putative ATG start codon could be detected within this additional sequence, novel primers (RAT-GFR α 4-ap5 and RAT-GFR α 4-ap6) were designed at the 5' end of this sequence to perform additional 5' RACE experiments.

First, a 5' RACE PCR was performed on rat heart Marathon Ready™ cDNA (Clontech). PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFR α 4-ap5 and RACE-ap1, 1 μ l of Advantage KlenTaq polymerase mix and 5 μ l of rat heart Marathon Ready™ cDNA. Samples were heated to 95°C for 30 s and cycling was done for 30 s at 95°C, 4 min at 72°C for 5 cycles, then 30 s at 95°C, 4 min at 70°C for 5 cycles, then 30 s at 95°C, 4 min at 68°C for 25 cycles, with a final step of 7 min at 68°C. A nested PCR was then performed on 1 μ l of the primary PCR reaction with primers RAT-GFR α 4-ap6 and RACE-ap2. PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFR α 4-ap6 and RACE-ap2, 1 μ l of Advantage KlenTaq polymerase mix and 1 μ l of primary PCR product. Cycling was done using exactly the same parameters as for the primary PCR. PCR products were analysed on a 1% agarose gel. A

- 31 -

fragment of approximately 200 bp was excised from the gel and cloned into the plasmid vector pCR2.1-TOPO using the TOPO TA cloning kit as described above. Sequencing of two resulting clones extended the rat GFR α -4 sequence with another 128 bp in the 5' direction. Based on this sequence, another primer set (RAT-GFR α 4-ap7 and RAT-GFR α 4-ap8) was designed to perform additional 5' RACE experiments. RACE PCR was performed on rat brain, heart and kidney Marathon Ready™ cDNA. PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFR α 4-ap7b and RACE-ap1, 1 μ l of Advantage KlenTaq polymerase mix and 5 μ l of rat heart, brain or kidney Marathon Ready™ cDNA. Samples were heated to 95°C for 30 s and cycling was done for 30 s at 95°C, 4 min at 72°C for 5 cycles, then 30 s at 95°C, 4 min at 70°C for 5 cycles, then 30 s at 95°C, 4 min at 68°C for 25 cycles, with a final step of 7 min at 68°C. A nested PCR was then performed on 1 μ l of the primary PCR reaction with primers RAT-GFR α 4-ap8 and RACE-ap2. PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFR α 4-ap8 and RACE-ap2, 1 μ l of Advantage KlenTaq polymerase mix and 1 μ l of primary PCR product. Cycling was done using exactly the same parameters as for the primary PCR. PCR products were analysed on a 1% agarose gel. Several fragments ranging in size from approximately 200 bp to 1200 bp were visible on the gel and were excised and cloned in vector pCR2.1-TOPO using TOPO-TA cloning. The inserts of several clones were sequenced. From these clones, the sequence of rat GFR α -4 could be extended in the 5' direction. Two different sequences

- 32 -

were identified. One sequence extended the ratGFR α -4 sequence with 215 bp in the 5' direction and included an in-frame start codon preceded by an in-frame upstream stop codon. The resulting predicted protein sequence (52 additional amino acid residues) includes a predicted signal peptide of 29 amino acid residues (as determined by the SPScan program included in the Wisconsin package version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin, USA; score 7.0, probability 1.171e-02). The other sequence determined by these 5' RACE experiments extended the ratGFR α -4 sequence with 552 bp in the 5' direction and also included an in-frame start codon preceded by an in-frame upstream stop codon. The most 3' 79 base pairs of this novel sequence were identical to the 3' 79 base pairs of the 215 bp sequence, but the rest of the sequence was different. The resulting predicted protein sequence (113 additional amino acid residues), however, did not have a predicted signal peptide sequence at the NH₂-terminus (SPScan, GCG package). The different partial cDNA sequences resulting from the subsequent 5' RACE experiments together with the sequences from the Incyte database were compared and merged into several possible rat GFR α -4 variants. In order to identify which of the identified variants are real, primers were designed 5' of the translation start codon (primers RAT-GFR α 4-sp4 and RAT-GFR α 4-sp5 for the "long" 5' variant resulting from the 552 bp RACE fragment and RAT-GFR α 4-sp6 for the "short" 5' variant resulting from the 215 bp RACE fragment) and 3' of the translation stop codon (RAT-GFR α 4-ap9 and RAT-GFR α 4-ap10). These primers were then used to amplify the full GFR α -4 coding sequences using cDNA derived from different rat tissues.

- 33 -

First, sequences coding for the "long" 5' variant were amplified by PCR. PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFR α 4-sp4 and RAT-GFR α 4-ap9, 1 μ l of Advantage KlenTaq polymerase mix and 5 μ l of rat heart, brain or kidney Marathon Ready™ cDNA. Samples were heated to 95°C for 1 min and cycling was done for 45 s at 95°C, 1 min at 57°C and 1 min at 72°C for 35 cycles, with a final step of 7 min at 72°C. A nested PCR was then performed on the primary PCR reaction with primers RAT-GFR α 4-sp5 and RAT-GFR α 4-ap10. PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFR α 4-sp5 and RAT-GFR α 4-ap10, 1 μ l of Advantage KlenTaq polymerase mix and 1 μ l of primary PCR product. Cycling was done using exactly the same parameters as for the primary PCR, except that 30 PCR cycles were done instead of 35. PCR products were analysed on a 1% agarose gel. Several fragments ranging in size from approximately 1000 to 1250 bp were excised from gel and cloned in vector pCR2.1-TOPO using TOPO-TA cloning. The inserts of several clones were sequenced.

Next, sequences coding for the "short" 5' variant were amplified by PCR. PCR reactions were performed in a total volume of 50 μ l, containing 1x GC cDNA PCR reaction buffer, 0.2 mM dNTP, 1 M GC-MELTä, 200 nM of primers RAT-GFR α 4-sp6 and RAT-GFR α 4-ap9, 1 μ l of Advantage KlenTaq polymerase mix and 5 μ l of rat heart Marathon Ready™ cDNA. Samples were heated to 95°C for 5 min and cycling was done for 30 s at 94°C, 1 min at 57°C and 2 min 30 s at 72°C for 35 cycles, with a final step of 7 min at 72°C. PCR products were

- 34 -

analysed on a 1% agarose gel. Several fragments ranging in size from approximately 1500 to 2200 bp were excised from gel and cloned in vector pCR2.1-TOPO using TOPO-TA cloning. The inserts of several clones were sequenced. Analysis of all the obtained sequences (16 resulting clones were completely sequenced) allowed the rat GFR α -4 DNA sequence to be divided into 6 sequence stretches common to all identified variants, with 5 intervening sequence stretches present or absent depending on the variant. All 5 intervening sequences contain 5' and 3' splice site consensus sites (GT at the 5' end and AG at the 3' end of the intron sequence) (Senapathy et al., 1990) (see table 4 below) and could thus potentially represent unspliced introns.

In order to strengthen the hypothesis that the identified variants could result from the conservation of unspliced introns in certain mRNA transcripts, the rat GFR α -4 sequence was compared to the genomic sequence of human GFR α -1 (Angrist et al., 1998). From this analysis, it was apparent that the GFR α -4 sequences common to all transcripts coincided with exons in GFR α -1 (see table 4 below). The intervening sequences absent in some transcripts coincided with intron sequences in human GFR α -1. Therefore, we considered all intervening sequences as unspliced introns. The intron present between exon 5 and exon 6 can be spliced out in two different ways and results in the presence of two different splice variants of rat GFR α -4, which we have called variant A and variant B.

Sequence 5 shows the consensus sequence for rat GFR α -4 including the intron sequences (intron 1: bp 125 to 684; intron 2: bp 1040 to 1088; intron 3: bp 1199 to 1278; intron 4: bp 1414 to 2154; intron 5A: bp 2247 to 2385 and intron 5B: bp 2231 to 2314). A polymorphism was detected at position 2244 in sequence 5, with T found in 50% of the sequenced clones and C in the other 50%. This polymorphism leads to an amino acid change in the protein (variant A) from W to R, in the hydrophobic region involved in GPI-anchoring. Figure 1 schematically shows the structure of the rat GFR α -4 gene together with the derived cDNA for splice variants A and B after splicing out of the intron sequences and the translated protein sequences of variants A and B with their characteristics. Table 4 shows the DNA sequence at the intron-exon boundaries together with the sizes of identified introns and exons. The right column shows the sizes of the corresponding exons in the genomic sequence of human GFR α -1 (from Angrist et al., 1998).

Table 4: Intron-exon structure of rat GFR α -4.

Exon	Size (bp)	Intron size (bp)	Splice acceptor	Splice donor	Corresponding GFR α -1 exon size (bp)
1	>124	560	---	GAGgtaaggaggt	---
2	355	49	ccctcaccagGGT	CCGgtgcgtgcgg	337
3	110	80	gcgcgcgcagGCC	TAGgtacgctggg	110
4	135	741	gtccctgcagGCA	TGGgtgagggggc	135
5	92	139 (varA) 84 (varB)	cactccatagATG	CGGgtaggtatgg TGGgtgctgtttc	182
6	>137	---	ttgtcccaagGTG cccttctcagGCA	-	753

The consensus sequence obtained by removing introns 1 to 4 and intron 5A (sequence 6; variant A) translates into a protein of 273 amino acid residues with a

- 36 -

calculated molecular mass of 29.7 kDa and an isoelectric point of 8.92 (sequence 8). The consensus sequence obtained by removing introns 1 to 4 and intron 5B (sequence 7; variant B) translates into a protein of 258 amino acid residues with a calculated molecular mass of 28.0 kDa and an isoelectric point of 8.91 (sequence 9). Figure 2 shows the alignment of variants A and B of rat GFR α -4. The protein sequences are both similar to the known GFR α sequences and only differ from each other in a small amino acid stretch at the carboxy-terminus. These two sequences probably represent biologically active GFR α -4 variants. Since all the other variants sequenced contain one or more intron sequences, they are probably intermediates of RNA processing. It is not clear why all these intermediates are present in cDNA derived from purified mRNA and why it is so difficult to amplify a cDNA sequence derived from a completely spliced mRNA transcript. GFR α -1 to -4 are characterized by a COOH-terminal sequence typical of a glycosyl-phosphatidyl inositol (GPI)-anchored protein, consisting of a hydrophobic region of 17-31 amino acid residues preceded by a hydrophilic sequence containing a stretch of three small amino acids such as Asp, Cys, Ala, Ser, Gly or Asn (Gerber et al., 1992). The rat GFR α -4 variant A protein sequence has a hydrophobic carboxy-terminus of 21 amino acid residues (position 253 to 273) preceded by two possible GPI cleavage sites (DSS at position 234 to 236 or NAG at position 250-252). Variant B has a shorter hydrophilic carboxy-terminus, implying that no GPI-anchoring is possible for this variant. This could mean that variant B is a soluble form of the rat GFR α -4 receptor. A predicted signal peptide of 29 amino acids is present in both

- 37 -

variants (as determined by the SPScan program included in the GCG package; score 7.0, probability 1.171e-02). In addition, one possible site for N-linked glycosylation (NVS at position 192 to 194 in the protein) is present.

Recently, a model has been proposed for the domain structure of GFR α 's based on the comparison of the sequences of mouse GFR α -1 to -3 and chicken GFR α -4 (Airaksinen et al., 1999). The model includes three conserved cysteine-rich domains joined together by less conserved adaptor sequences. The molecules are anchored to the membrane by a GPI-anchor. Rat GFR α -4 conforms partly to this model, since it also contains the second and third cysteine-rich region and a possible GPI-anchor (at least for variant A). However, it differs significantly from the other GFR α 's in that the first cysteine-rich region is absent. Figure 3 shows the alignment of rat GFR α -4 variants A and B with rat GFR α -1 (EMBL acc. no. U59486), rat GFR α -2 (EMBL acc. no. AF003825), mouse GFR α -3 (EMBL acc. no. AB008833) and chicken GFR α -4 (EMBL acc. no. AF045162). The alignment was done using the ClustalW alignment program (EMBL, Heidelberg, Germany). The percentage identity and percentage similarity between members of the GFR α family were calculated by pairwise comparison of the sequences using the GeneDoc software tool (version 2.5.000) and the results are presented in Table 5 below.

30

Table 5: % identity and % similarity (between brackets) between members of the GFR α family. Accession numbers of the sequences used in the analysis are mentioned in the text.

5

	rGFR α -1	rGFR α -2	mGFR α -3	cGFR α -4	rGFR α -4 (A)	rGFR α -4 (B)
rGFR α -1	100	43 (60)	15 (23)	38 (55)	20 (29)	20 (28)
rGFR α -2		100	18 (28)	40 (56)	21 (32)	21 (31)
mGFR α -3			100	16 (25)	22 (30)	20 (29)
cGFR α -4				100	27 (37)	26 (35)
rGFR α -4 (A)					100	92 (92)
rGFR α -4 (B)						100

10

Four members of the GDNF family of neurotrophic factors have been identified so far (GDNF, NTN, PSP, EVN/ARTN). All four signal through binding to a specific GPI-linked GFR α receptor (GFR α -1 for GDNF, GFR α -2 for NTN, GFR α -3 for EVN/ARTN and (chicken) GFR α -4 for PSP) in combination with a common transmembrane tyrosine kinase, cRET. GFR α -4, the coreceptor for PSP, has been identified in chicken only and no mammalian counterpart has been found yet.

20

The similarity between the rat GFR α -4 described in the present application and the chicken GFR α -4 is 37% (27% identity) suggesting that rat GFR α -4 is a novel member of the GFR α family. GFR α -4 could be the mammalian persephin receptor or, alternatively, could be the receptor for an unidentified GDNF family member.

25

30

Specific binding of persephin to GFR α -4.

Constructs for the expression of soluble GFR α -IgG-Fc fusion proteins were made as follows. cDNA regions of human GFR α -1, GFR α -2 and GFR α -3, chicken GFR α -4 and rat GFR α -4 variant A (coding for amino acid residues 27 to 427, 20 to 431, 28 to 371, 20 to 399 and 29 to

35

- 39 -

252, respectively), excluding the sequences coding for the signal peptide and for the COOH-terminal hydrophobic region involved in GPI-anchoring, were cloned in-frame in the expression vector Signal pIg plus (R&D Systems Europe Ltd, Abingdon, UK). The inserts of all constructs were confirmed by complete DNA sequence analysis. The resulting proteins expressed from these constructs contain a 17 amino acid residue NH₂-terminal CD33 signal peptide, the respective GFR α protein region and a 243 amino acid residue COOH-terminal human IgG₁-Fc fusion domain. Fusion proteins were expressed in CHO cells and purified as described. Chinese hamster ovary (CHO) cells were routinely cultured in DMEM/F12 medium supplemented with 10 % heat inactivated fetal calf serum. Cells were transfected with GFR α -IgGFc fusion constructs using an optimized Lipofectamine Plus method. For this, a total amount of 6.5 μ g DNA was incubated with 17.5 μ l PLUS reagent in 750 μ l serum free medium for 15 min at room temperature. Lipofectamine was diluted 50-fold into serum free culture medium, 750 μ l of this mixture was added to the DNA solution. Following a 15 min incubation at room temperature, 3.5 ml serum free medium was added, and the mixture was brought onto the cells (in a 100 mm petridish). The cells were incubated for 3h at 37°C in 5 % CO₂, after which 5 ml of culture medium, containing 20 % heat inactivated fetal calf serum, was added. 24 h later, the medium was changed into regular culture medium. Transfection efficiencies using these optimized conditions were typically 50-60%. For permanent transfections the selection medium contained either 800 μ g G418 or 800 μ g G418 and 800 μ g hygromycin. Antibiotic resistant clones were expanded

- 40 -

and assayed for expression using specific antibodies. GFR α -IgGFc fusion proteins were purified from the medium of permanently or transiently transfected CHO cells by protein A chromatography. Bound protein was
5 eluted with 0.1 M Na-citrate, pH 3.0 and collected into 1 M Tris buffer, pH 8.4 (dilution ratio 1:6). Protein concentration was estimated by absorbance at 280 nm using an extinction coefficient of 1.5. Surface plasmon resonance (SPR) experiments were performed at
10 25°C using a BIACORE 3000 instrument (Biacore AB, Uppsala, Sweden). Sensor chip CM5, the amine coupling kit and buffers used were also obtained from Biacore AB. Recombinant PSP, NTN, EVN/ART and GDNF were used as immobilised ligands. Recombinant human GDNF was
15 obtained from R&D Systems Europe Ltd. (Abingdon, UK). NH₂-terminally 6His-tagged recombinant human NTN, rat PSP and human EVN/ART were produced in *E. coli* as described previously (Creedon et al., 1997). The carboxylated matrix of a CM5 sensor chip was first
20 activated with a 1:1 mixture of 400 mM N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide and 100 mM N-hydroxy-succinimide for 10 min. Recombinant neurotrophic factors were applied onto the activated surface in 10 mM sodium acetate buffer, pH 4.5 at a
25 flow rate of 5 μ l/min. Unreacted carboxyl groups were blocked with 1 M ethanolamine-HCl. For binding experiments, soluble GFR α -IgGFc fusion proteins were superfused using the kinject program at 30 μ l/min. Concentrations of GFR α -IgGFc used in kinetic
30 experiments were between 1 and 100 nM in Hepes buffered saline (150 mM NaCl, 3.5 mM EDTA sodium salt, 0.005% polysorbate 20, 10 mM Hepes, pH 7.4). The association of the GFR α receptors to the immobilised ligands was monitored for 3 min and the dissociation

- 41 -

for 1 min, followed by regeneration with 10 mM glycine buffer. Dissociation was initiated by superfusion with Hepes buffered saline. To improve the quality of sensor data, double referencing was used (Myszka, 1999). Data were analyzed using a global analysis with the BIACORE evaluation software (version 3.0.1). Global analysis calculates the association rate (k_a) and dissociation rate (k_d) simultaneously and the apparent equilibrium dissociation constant (K_D) is then calculated as k_d/k_a . A simple 1:1 Langmuir model was used to fit the data. Specific binding to PSP could be detected with both rat and chicken GFR α -4-IgGFc fusion proteins. The observed binding of GFR α -4-IgGFc was specific as there was no binding to GDNF, NTN or EVN/ART. Control experiments confirmed binding of GFR-1 to GDNF, of GFR α -2 to NTN and of GFR α -3 to EVN/ART. From the binding curves obtained using three determinations at differing concentrations of rat and chicken GFR α -4-IgGFc, the binding constants k_a (association rate) and k_d (dissociation rate) were derived (Table 6).

Table 6: Persephin binding to chicken GFR α -4 and rat GFR α -4.

Binding constants for chicken GFR α -4-IgGFc and rat GFR α -4-IgGFc binding to immobilised persephin as determined by SPR. The mean association rate (k_a), dissociation rate (k_d) and apparent equilibrium dissociation constant (K_D) \pm standard errors were derived from the binding curves obtained using 3 determinations at differing concentrations of the respective soluble receptors.

- 42 -

	k_a (1/Ms)	k_d (1/s)	K_D (M)
chicken	2.3 ± 2.6	$8.8 \pm 5.1 \times$	$5.4 \pm 2.9 \times$
GFR α -4	$\times 10^4$	10^{-4}	10^{-9}
rat GFR α -4	2.7 ± 1.6	$1.1 \pm 0.2 \times$	$5.9 \pm 2.8 \times$
	$\times 10^4$	10^{-3}	10^{-9}

5

Although apparent K_D values were very similar for both fusion proteins, R_{MAX} values were significantly different. Binding levels of ~1000 relative units (RU) were routinely obtained with chicken GFR α -4-IgGFc, whereas binding levels of rat GFR α -4-IgGFc were approximately 20 times lower, around 50-60 RU. This could be due to differences in the concentration of active chicken GFR-4-IgGFc and rat GFR α -4-IgGFc fusion protein. The calculated equilibrium dissociation constant K_D of 5.9 ± 2.8 nM ($n=3$) suggests that rat GFR α -4 is a receptor specific for persephin.

10

15

Northern blot analysis.

Northern blots containing 2 μ g of poly(A)-rich RNA derived from different rodent tissues (mouse MTNTM blot, mouse embryo MTNTM blot and rat MTNTM blot; Clontech Laboratories) were hybridized according to the manufacturer's instructions with a α -[³²P]-dCTP random-priming labeled (HighPrime kit, Roche Diagnostics) 948 bp fragment derived from the rat GFR α -4 coding sequence (as in sequence ID No. 6). Stringency washes were performed in 0.1x SSC / 0.1 % SDS at 50°C (the two mouse blots) or 55°C (the rat blot). The results are shown in Figure 4. In rat, a very weak signal could be detected around 2.3 kb in heart, brain, liver and testis. An even weaker second transcript was present around 1.4 kb in the same tissues. In mouse, a 1.35 kb transcript was most

20

25

30

- 43 -

intense in brain and testis, with a much weaker signal present around 2 kb. Very low mRNA expression of the 1.35 kb transcript was also present in 15-day and 17-day mouse embryo. The size of the smaller transcript is in agreement with the predicted size of the GFR α -4 coding sequence (\pm 880 bp + the 3' untranslated region of 570 bp).

Chromosomal localization of rat, mouse and human GFR α -

10 4.

A 0.95 kb rat GFR α -4 cDNA fragment (containing the full rat GFR α -4 coding sequence of variant A) and a 2.3 kb fragment corresponding to the rat GFR α -4 genomic sequence (see sequence ID No. 5) were used as probes in fluorescent *in situ* hybridization (FISH) analysis on rat chromosomes. These probes were partially overlapping. A mixture of the two probes (1 μ g total DNA) was labeled with digoxigenin-11-dUTP (Roche Diagnostics, Mannheim, Germany) by nick translation (Life Technologies) producing a final probe fragment size of 200-400 bp. The labeled probe was mixed with hybridization buffer (50% formamide, 2x SSC, 10% dextran sulfate). After denaturation, the mixture was placed on metaphase rat chromosome slides (Islam and Levan, 1987, Helou et al., 1998) denatured at 72°C for 2 min in 70% formamide, 2x SSC. After hybridization for 48 h at 37°C, preparations were washed for 15 min in 50 % formamide, 2x SSC. Detection of labeled chromosomes was done by standard FITC anti-digoxigenin. Chromosome spreads were counterstained with 4', 6-diamidino-2-phenylindole (DAPI). Results were derived from micrographs of 100 different cells. Due to the small size of the probes there was

- 44 -

considerable background. However, most studied cells showed label at position RNO3q36 (Figure 5). About 35 % of the metaphase studies showed "double spot" label at both homologues of RNO3, whereas about 50 % had double spots on only one of the homologues or "single spot" label on both homologues. No other chromosomal site showed label in several cells. Based on comparative mapping, the corresponding mouse locus would be expected to be located at MMU2 (band F), whereas a possible human location for the gene would be HSA2, HSA15 or HSA20. In agreement with this, the genomic mouse and human GFR α -4 sequences identified in the EMBL database (Accession No. AF155960 for mouse and AC017113 for human) are derived from mouse chromosome 2 (BAC clone 389B9) and from human chromosome 2 (EMBL accession number AC013324; BAC388_K_24map2), respectively.

- 45 -

References

- Airaksinen, M.S., Titievsky, A. & Saarma, M. (1999)
GDNF family neurotrophic factor signaling: four
5 masters, one servant? *Mol. Cell. Neurosci.* 13, 313-
325.
- Altschul, S.F., Gish, W., Miller, W., Myers, E.W. &
Lipman, D.J. (1990) Basic local alignment search tool,
10 *J. Mol. Biol.* 215, 403-410.
- Angrist, M., Jing, S., Bolk, S., Bentley, K.,
Nallasamy, S., Halushka, M., Fox, G.M. & Chakravarti,
A. (1998) Human GFR α 1: cloning, mapping, genomic
15 structure, and evaluation as a candidate gene for
Hirschsprung disease susceptibility. *Genomics* 48, 354-
362.
- Baloh, R.H., Tansey, M.G., Golden, J.P., Creedon,
20 D.J., Heuckeroth, R.O., Keck, C.L., Zimonjic, D.B.,
Popescu, N.C., Johnson, E.M. & Milbrandt, J. (1997)
TrnR2, a novel receptor that mediates neurturin and
GDNF signaling through Ret. *Neuron* 18, 793-802.
- 25 Baloh, R.H., Gorodinsky, A., Golden, J.P., Tansey,
M.G., Keck, C.L., Popescu, N.C., Johnson, E.M. &
Milbrandt, J. (1998a) GFR α 3 is an orphan member of the
GDNF/neurturin/persephin receptor family. *Proc. Natl.*
Acad. Sci. USA 95, 5801-5806.
- 30 Baloh, R.H., Tansey, M.G., Lampe, P.A., Fahrner, T.J.,
Enomoto, H., Simburger, K.S., Leitner, M.L., Araki,
T., Johnsson, E.M. & Milbrandt, J. (1998b) Artemin, a
novel member of the GDNF ligand family, supports

- 46 -

peripheral and central neurons and signals through the GFR α -3-RET receptor complex. *Neuron* 21,1291-1302.

- 5 Beck, K.D., Valverde, J., Alexi, T., Poulsen, K.,
Moffat, B., Vandlen, RA., Rosenthal, A. & Hefti, F.
(1995) Mesencephalic dopaminergic neurons protected by
GDNF from axotomy-induced degeneration in the adult
brain. *Nature* 373,339-341.
- 10 Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I.,
Robert J.J., Mallet, J. & Horellou, P. (1997)
Intrastriatal injection of an adenoviral vector
expressing glial-cell-line-derived neurotrophic factor
prevents dopaminergic neuron degeneration and
15 behavioral impairment in a rat model of Parkinson
disease. *Proc. Natl. Acad. Sci. USA* 94,8818-8823.
- Buj-Bello, A., Buchman, V.L., Horton, A., Rosenthal,
A. & Davies A.M. (1995) GDNF is an age-specific
20 survival factor for sensory and autonomic neurons.
Neuron 15,821-828.
- Buj-Bello, A., Adu, J., Piñón, L.G.P., Horton, A.,
Thompson, J., Rosenthal, A., Chinchetru, M., Buchman,
25 V.L. & Davies, A.M. (1997) Neurturin responsiveness
requires a GPI-linked receptor and the Ret receptor
tyrosine kinase. *Nature* 387,721-724.
- Choi-Lundberg, D.L., Lin, Q., Chang, Y.N., Chiang,
30 Y.L., Hay, C.M., Mohajeri, H., Davidson, B.L. & Bohn,
M.C. (1997) Dopaminergic neurons protected from
degeneration by GDNF gene therapy. *Science*. 275,838-
841.

- 47 -

- Creedon, D.J., Tansey, M.G., Baloh, R.H., Osborne, P.A., Lampe, P.A., Fahrner, T.J., Heuckeroth, R.O., Milbrandt, J. & Johnson, E.M. (1997) Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. *Proc. Natl. Acad. Sci. USA*, 94, 7018-7023.
- Durbec, P., Marcos-Gutierrez, C.V., Kilkenny, C., Grigoriou, M., Wartiovaara, K., Suvanto, P., Smith, D., Ponder, B., Costantini, F., Saarma, M., Sariola, H. & Pachnis, V. (1996) GDNF signalling through the RET receptor tyrosine kinase. *Nature* 381, 789-793.
- Enokido, Y., de Sauvage, F., Hongo, J.-A., Ninkina, N., Rosenthal, A., Buchman, V.L. & Davies, A.M. (1998) GFR α -4 and the tyrosine kinase Ret form a functional receptor complex for persephin. *Current Biology* 8, 1019-1022.
- Gash, D.M., Zhang, Z., Ovadia, A., Cass, W.A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P.A., Collins, F., Hoffer, B.J. & Gerhardt, G.A. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. *Nature* 380, 252-255.
- Gerber, L.D., Kodukula, K. & Udenfriend, S. (1992) Phosphatidylinositol glycan (PI-G) anchored membrane proteins. *J. Biol. Chem.* 267, 12168-12173.
- GFR α Nomenclature Committee (1997) Nomenclature of GPI-linked receptors for the GDNF ligand family. *Neuron* 19, 485.

- 48 -

- Helou, K., Walther, L., Günther, E., Klinga-Levan, K. & Levan, G. (1998) Cytogenetic orientation of the rat major histocompatibility complex (MHC) on chromosome 20. *Immunogenetics* 47:166-169.
- 5 Henderson, C.E., Phillips, H.S., Pollock, R.A., Davies, A.M., Lemeulle, C., Armanini, M., Simmons, L., Moffet, B., Vandlen, R.A., Koliatsos, V.E. & Rosenthal, A. (1994) GDNF: a potent survival factor
10 for motoneurons present in peripheral nerve and muscle. *Science* 266,1062-1064.
- Islam, M.Q. & Levan, G. (1987) A new fixation procedure for improved quality G-bands in routine
15 cytogenetic work. *Hereditas* 107:127-130.
- Jing, S., Wen, D., Yu, Y., Holst, P.L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., Louis, J.-C., Hu, S., Altrock, B.W. & Fox, G.M. (1996)
20 GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR- α , a novel receptor for GDNF. *Cell* 85, 1113-1124.
- Jing, S., Yu, Y., Fang, M., Hu, Z., Holst, P.L., Boone, T., Delaney, J., Schultz, H., Zhou, R. & Fox, G.M. (1997) GFR α -2 and GFR α -3 are two new receptors
25 for ligands of the GDNF family. *J. Biol. Chem.* 272,33111-33117.
- 30 Kingsley, D.M. (1994) The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. *Genes & Development* 8,133-146.

- 49 -

- Klein, R.D., Sherman, D., Ho, W.-H., Stone, D.,
Bennett, G.L., Moffat, B., Vandlen, R., Simmons, L.,
Gu, Q., Hongo, J.-A., Devaux, B., Poulsen, K.,
Armanini, M., Nozaki, C., Asai, N., Goddard, A.,
5 Phillips, H., Henderson, C.E., Takahashi, M. &
Rosenthal, A. (1997) A GPI-linked protein that
interacts with Ret to form a candidate neurturin
receptor. *Nature* 387, 717-721.
- 10 Kotzbauer, P.T., Lampe, P.A., Heuckeroth, R.O.,
Golden, J.P., Creedon, D.J., Johnson, E.M. &
Milbrandt, J. (1996) Neurturin, a relative of glial-
cell-line-derived neurotrophic factor. *Nature* 384,
467-470.
- 15 Lin, L.-F.H., Doherty, D.H., Lile, J.D., Bektesh, S. &
Collins, F. (1993) GDNF: a glial cell line-derived
neurotrophic factor for midbrain dopaminergic neurons.
Science 260, 1130-1132.
- 20 Mandel, R.J., Spratt, S.K., Snyder, R.O. & Leff, S.E.
(1997) Midbrain injection of recombinant adeno-
associated virus encoding rat glial cell line-derived
neurotrophic factor protects nigral neurons in a
25 progressive 6-hydroxydopamine-induced degeneration
model of Parkinson's disease in rats. *Proc. Natl.*
Acad. Sci. USA 94, 14083-14088.
- 30 Masure, S., Cik, M., Pangalos, M.N., Bonaventure, P.,
Verhasselt, P., Lesage, A.S., Leysen, J.E. & Gordon
R.D. (1998) Molecular cloning, expression and tissue
distribution of glial-cell-line-derived neurotrophic
factor family receptor α -3 (GFR α -3). *Eur. J. Biochem.*
251, 622-630.

- 50 -

- Masure, S., Geerts, H., Cik, M., Hoefnagel, E.,
Tuytelaars, A., Harris, S., Lesage, A.S.J., Leysen,
J.E., van der Helm, L., Verhasselt, P., Yon, J. &
Grodon, R.D. (1999) Enovin, a novel member of the GDNF
5 family of neurotrophic growth factors with growth
promoting and neuroprotective effects on neuronal
cells. Masure et al., (1999) Eur. J. Biochem.
266:892-902.
- 10 Milbrandt, J., de Sauvage, F.J., Fahrner, T.J., Baloh,
R.H., Leitner, M.L., Tansey, M.G., Lampe, P.A.,
Heuckeroth, R.O., Kotzbauer, P.T., Simburger, K.S.,
Golden, J.P., Davies, J.A., Vejsada, R., Kato, A.C.,
Hynes, M., Sherman, D., Nishimura, M., Wang, L.C.,
15 Vandlen, R., Moffat, B., Klein, R.D., Poulsen, K.,
Gray, C., Garces, A., Henderson, C.E., Phillips, H.S.
& Johnson, E.M. Jr. (1998) Persephin, a novel
neurotrophic factor related to GDNF and neurturin.
Neuron 20,245-253.
- 20 Mount, H.T., Dean, D.O., Alberch, J., Dreyfus, C.F. &
Black, I.B. (1995) Glial cell line-derived
neurotrophic factor promotes the survival and
morphologic differentiation of Purkinje cells. *Proc.*
25 *Natl. Acad. Sci. USA* 92,9092-9096.
- Myszka, D.G. (1999) Improving biosensor analysis. *J.*
Mol. Recognit. 12, 279-284.
- 30 Naveilhan, P., Baudet, C., Mikaelis, A., Shen, L.,
Westphal, H. & Ernfors, P. (1998) Expression and
regulation of GFR α 3, a glial cell line-derived
neurotrophic factor family receptor. *Proc. Natl. Acad.*
Sci. USA 95,1295-1300.

- 51 -

- Oppenheim, R.W., Houenou, L.J., Johnson, J.E., Lin, L.F., Li, L., Lo, A.C., Newsome, A.L., Prevet, D.M. & Wang, S. (1995) Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. *Nature* 373,344-346.
- Sanicola, M., Hession, C., Worley, D., Carmillo, P., Ehrenfels, C., Walus, L., Robinson, S., Jaworski, G., Wei, H., Tizard, R., Whitty, A., Pepinsky, R.B. & Cate, R.L. (1997) Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. *Proc. Natl. Acad. Sci. USA* 94, 6238-6243.
- Senapathy, P., Shapiro, M.B. & Harris, N.L. (1990) Splice junctions, branch point sites, and exons: sequence statistics, identification, and applications to genome project. *Methods Enzymol.* 183,252-278.
- Suvanto, P., Wartiovaara, K., Lindahl, M., Arumäe, U., Moshnyakov, M., Horelli-Kuitunen, N., Airaksinen, M.S., Palotie, A., Sariola, H. & Saarma, M. (1997) Cloning, mRNA distribution and chromosomal localisation of the gene for glial cell line-derived neurotrophic factor receptor β , a homologue to GDNFR- α . *Human Mol. Genet.* 6, 1267-1273.
- Thompson, J., Doxakis, E., Piñón, L.G.P., Strachan, P., Buj-Bello, A., Wyatt, S., Buchman, V.L. & Davies, A.M. (1998) GFR α -4, a new GDNF family receptor. *Mol. Cell. Neurosci.* 11, 117-126.
- Tomac, A., Lindqvist, E., Lin, L.F., Ogren, S.O., Young, D., Hoffer, B.J. & Olson, L. (1995) Protection

- 52 -

and repair of the nigrostriatal dopaminergic system by GDNF in vivo. *Nature* 373,335-339.

5 Treanor, J.J.S., Goodman, L., de Sauvage, F., Stone, D.M., Poulsen, K.T., Beck, C.D., Gray, C., Armanini, M.P., Pollock, R.A., Hefti, F., Phillips, H.S., Goddard, A., Moore, M.W., Buj-Bello, A., Davies, A.M., Asai, N., Takahashi, M., Vandlen, R., Henderson, C.E. & Rosenthal, A. (1996) Characterization of a
10 multicomponent receptor for GDNF. *Nature* 382, 80-83.

Trupp, M., Arenas, E., Fainzilber, M., Nilsson, A.S., Sieber, B.A., Grigoriou, M., Kilkenny, C., Salazar-Grueso, E., Pachnis, V., Arumäe, U., Sariola, H.,
15 Saarma, M. & Ibanez, C.F. (1996) Functional receptor for GDNF encoded by the c-ret proto-oncogene. *Nature* 381, 785-788.

Widenfalk, J., Nosrat, C., Tomac, A., Westphal, H.,
20 Hoffer, B. & Olson, L. (1997) Neurturin and glial cell line-derived neurotrophic factor receptor- β (GDNFR- β), novel proteins related to GDNF and GDNFR- α with specific cellular patterns of expression suggesting roles in the developing and adult nervous system and
25 in peripheral organs. *J. Neurosci.* 17,8506-8519.

Widenfalk, J., Tomac, A., Lindqvist, E., Hoffer, B. & Olson, L. (1998) GFR α -3, a protein related to GFR α -1, is expressed in developing peripheral neurons and
30 ensheathing cells. *Eur. J. Neurosci.* 10,1508-1517.

Worby, C.A., Vega, Q.C., Zhao, Y., Chao, H. H.-J., Seasholtz, A.F. & Dixon, J.E. (1996) Glial cell line-derived neurotrophic factor signals through the RET

- 53 -

receptor and activates mitogen-activated protein kinase. *J. Biol. Chem.* 271, 23619-23622.

5 Worby, C.A., Vega, Q.C., Chao, H.H.J., Seasholtz, A.F., Thompson, R.C. & Dixon J.E. (1998) Identification and characterization of GFR α -3, a novel co-receptor belonging to the glial cell line-derived neurotrophic receptor family. *J. Biol. Chem.* 273,3502-3508.

10 Yan, Q., Matheson, C. & Lopez, O.T. (1995) In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. *Nature* 373,341-344.

List of abbreviations

	ARTN	artemin
	BLAST	basic local alignment search tool
5	bp	base pairs
	cDNA	complementary DNA
	CNS	central nervous system
	EST	expressed sequence tag
	EVN	enovin
10	GDNF	glial cell-line derived neurotrophic factor
	GFR α	GDNF family receptor α
	GPI	glycosyl phosphatidyl inositol
	NTN	neurturin
15	PCR	polymerase chain reaction
	PNS	peripheral nervous system
	PSP	persephin
	SSP	smallest sum probability
	TGF- β	transforming growth factor β
20		

Claims

1. An isolated or substantially pure form of a nucleic acid molecule encoding a mammalian GDNF family receptor α -4 (GFR α -4).
5

2. The nucleic acid molecule of claim 1 which is derived from a rat, mouse or human.

10 3. The nucleic acid molecule of claim 1 or 2 encoding a mammalian GDNF family receptor α -4 (GFR α -4) having the amino acid sequence illustrated in Sequence ID No. 8 or 9 or encoding a functional equivalent or bioprecursor of said receptor.

15

4. A nucleic acid molecule according to any of claims 1 to 3 which is a DNA molecule.

20 5. A nucleic acid molecule according to claim 4, wherein said DNA molecule is a cDNA molecule.

25 6. A nucleic acid molecule according to any preceding claim having the sequence illustrated in any of SEQ ID Nos 5, 6, or 7 or the complementary sequence thereof.

30 7. A nucleic acid molecule capable of hybridising to the molecule of any of claims 1 to 6 or the complementary sequences thereof under conditions of high stringency.

8. A GFR α -4 receptor encoded by a nucleic acid molecule according to any of claims 1 to 6.

- 56 -

9. A DNA expression vector comprising a nucleic acid molecule according to any of claims 4 to 6.

5 10. A host cell transformed or transfected with the vector according to claim 9.

11. A host cell according to claim 10, which cell is a eukaryotic cell.

10 12. A host cell according to claim 10 or 11 wherein said cell is a mammalian cell.

13. A host cell according to claim 12 which cell is a human embryonic kidney cell HEK293 or a Cos-7
15 cell.

14. A transgenic cell, tissue or organism comprising a transgene capable of expressing a GFR α -4 receptor protein having the amino acid sequence
20 illustrated in Sequence ID No's. 8 or 9 or the amino acid sequence of a functional equivalent or bioprecursor thereof.

15. A transgenic cell tissue or organism
25 according to claim 14, wherein said transgene comprises a nucleic acid molecule according to any of claims 1 to 6.

16. A GFR α -4 receptor protein or a functional
30 equivalent derivative or bioprecursor thereof, expressed by the cell according to any of claims 10 to 15.

17. A HEK293 or Cos-7 cell line trasfected or transformed with the expression vector of claim 9.

5 18. An antisense molecule comprising a nucleic acid which is capable of hybridising to the nucleic acid according to any of claims 1 to 6.

10 19. A molecule according to claim 18 for use as a medicament.

20. Use of a molecule according to claim 18 in the manufacture of a medicament for treating pain or carcinoma.

15 21. An isolated receptor having the amino acid sequence as illustrated in any of SEQUENCE ID No 8 or 9 or the amino acid sequence of a functional equivalent or bioprecursor of said receptor.

20 22. A pharmaceutical composition comprising a nucleic acid molecule according to any of claims 1 to 6 together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

25 23. A pharmaceutical composition comprising a molecule according to claim 18 or a receptor according to claim 21 together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

30 24. A compound which acts as an agonist or an antagonist in relation to the receptor of claim 21.

25. A pharmaceutical composition comprising an agonist or an antagonist according to claim 24

together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.

26. A method of determining whether a compound
5 is an agonist or an antagonist in relation to a
receptor GFR α -4 according to any of claims 8 or 21,
which method comprises contacting a cell expressing
said receptor with said compound to be tested and
monitoring the level of any GFR α 4 mediated functional
10 or biological response.

27. A method according to claim 26 wherein said
cell is a cell according to any of claims 10 to 15.

15 28. A method according to claim 26 or 27 wherein
the GFR α -4 mediated functional or biological response
comprises the level of phosphorylation in said cell.

29. A method of determining whether a compound
20 is an agonist, antagonist or a ligand in relation to
GFR α -4 receptor, according to claims 8 or 11, which
method comprises contacting a membrane preparation of
cells expressing said GFR α -4 with said compound in the
presence of cRET or similar protein which interacts
25 with GFR α -4 in the signal transduction pathway of
which GFR α 4 is a component and monitoring the level of
any interaction of GFR α -4 with cRET or said similar
protein.

30 30. A method of producing an antagonist or
agonist of GFR α -4 comprising the steps of a method of
any one of claims 26 to 29; and additionally
(i) synthesizing the compound obtained or
identified in said method or a

physiologically acceptable analog or derivative thereof in an amount sufficient to provide said antagonist or agonist in a therapeutically effective amount to a patient; and/or

- (ii) combining the compound obtained or identified in said method or an analog or derivative thereof with a pharmaceutically acceptable carrier.

31. A compound identifiable as an agonist by the method according to any of claims 26 to 29 for use as a medicament.

32. Use of a compound identifiable as an agonist by the method according to any of claims 26 to 29 in the preparation of a medicament for the treatment of neurodegenerative diseases, Alzheimers disease, Parkinsons disease, Motor Neuron Disease, peripheral neuropathy, spinal cord injury, familial hirschsprung disease, carcinomas and diseases associated with GFR α 4 receptor dysfunction.

33. A compound identifiable as an antagonist by the method according to any of claims 26 to 29 for use as a medicament.

34. Use of a compound identifiable as an antagonist by the method according to any of claims 26 to 29 in the preparation of a medicament for the treatment of carcinomas or in alleviating pain.

35. A pharmaceutical composition comprising a compound according to claim 31 or 32 together with a

- 60 -

pharmaceutically acceptable carrier, diluent or excipient therefor.

5 36. An antibody specific for GFR α -4 receptor protein having an amino acid sequence as illustrated in Sequence ID No's. 8 or 9 or an amino acid sequence of a functional equivalent or bioprecursor of said receptor.

10 37. A pharmaceutical composition comprising an antibody according to claim 36 together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

15 38. A method of identifying ligands for GFR α -4 receptor protein, which method comprises contacting a receptor according to claim 8 or 11 with a cell extract or a compound to be tested and isolating any molecules bound to said receptor.

20 39. A method of determining whether a compound is a ligand for GFR α -4 receptor, which method comprises contacting a cell expressing said receptor according to any of claims 10 to 15 with said compound
25 and monitoring the level of any GFR α -4 mediated functional or biological response.

30 40. A method according to claim 39 which comprises monitoring the level of phosphorylation in said cell.

 41. A compound identifiable as a ligand for GFR α -4 according to the method of claims 39 or 40 for use as a medicament.

42. Use of a compound identifiable according to the method of claims 39 or 40 in the preparation of a medicament for the treatment of neurodegenerative diseases, Alzheimers disease, Parkinsons disease,
5 Motor Neuron Disease, peripheral neuropathy, spinal cord injury, familial hirschsprung disease in addition to carcinoma and diseases associated with GFR α -4 dysfunction.

10 43. A kit for determining whether a compound is an agonist or an antagonist of GFR α -4 receptor protein which kit comprises a cell according to any of claims 10 to 15, means for contacting said cell with said compound and means for monitoring the level of GFR α -4
15 mediated functional or biological response in said cell.

44. A kit according to claim 43, wherein said GFR α -4 mediated functional or biological response
20 comprises the level of phosphorylation in said cell.

45. A diagnostic kit including a probe which comprises any of, a nucleic acid molecule according to any of claims 1 to 6 or a fragment thereof or an
25 antisense molecule according to claim 18 and means for contacting biological material to be tested with said probe.

46. A kit for determining whether a compound is
30 a ligand of GFR α -4 receptor protein, which kit comprises a membrane preparation from cells expressing GFR α -4, means for contacting said preparation with said compound in the presence of cRET or a similar protein involved in the signal transduction pathway of

which GFR α -4 is a component and means for measuring any interaction between GFR α -4 and cRET or said similar protein.





Fig 1



10/019337

rGFra-5(A) : MMSGAYLRVLNERPGQAVLWSLGCQRCQSASSTEGNRCVVEAAEACTADEQC : 50
 rGFra-5(B) : MMSGAYLRVLNERPGQAVLWSLGCQRCQSASSTEGNRCVVEAAEACTADEQC : 50

rGFra-5(A) : QQLRSEYVAQCLGRAGWRGPGSCVRSRCRRALRRFFARGPPALTHALLFC : 100
 rGFra-5(B) : QQLRSEYVAQCLGRAGWRGPGSCVRSRCRRALRRFFARGPPALTHALLFC : 100

rGFra-5(A) : GCEGPACAEERRRQTFAPACAFSGPQLAPPSCLKPLDRCSRRRCRPRLEA : 150
 rGFra-5(B) : GCEGPACAEERRRQTFAPACAFSGPQLAPPSCLKPLDRCSRRRCRPRLEA : 150

rGFra-5(A) : FQASCAPAPGSRDGCPEEGGPRCLRAYAGLVGTVVTENYLDNV SARVAPW : 200
 rGFra-5(B) : FQASCAPAPGSRDGCPEEGGPRCLRAYAGLVGTVVTENYLDNV SARVAPW : 200

rGFra-5(A) : CGCEASGNRRREECEAFERKLFTRNPPCLDGAIQAFDSSQPSVLQDQWNP YQN : 250
 rGFra-5(B) : CGCEASGNRRREECEAFERKLFTRNPPCLDGAIQAFDSSQPSVLQDQWNP YQN : 250

rGFra-5(A) : AGCCFLNVSSMSILTALALQALL : 273
 rGFra-5(B) : AGQAKVEA----- : 258

Fig 2

10/019

Fig 4






Fig 5

A



B



SEQUENCE LISTING

<110> Janssen Pharmaceutica N.V. et al

<120> Neurotrophic Factor Receptor

<130> 53202/001

<140> PCT/EP00/04918

<141> 2000-05-26

<150> GB 9915200.1

<151> 1999-05-29

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 792

<212> DNA

<213> Mus musculus

<400> 1

```

gtgcgccgag cgccggcgcc agactttcgc gcccgccctgc gcgttctcgc gcccggggtt 60
ggtgccgccc tcttgccctg agcccttgga gcgctgcgag cgcagccgcc tgtgccggtg 120
cgtgcgtgag gggcggggtg ggccgctcac ccgcgtccgg gcgcgcgcag gcccggtctc 180
cttgccctcc aggcctcatg cgctcccgcg cccggctccc gcgaccgctg cccggaggag 240
gggggcccgc gttgtctgag cgtctacgca ggccctcatg gcaccgtggt ccccccaac 300
tacctggaca acgtgagcgc gcgcgttgag ccctggtgag gctgtgcggc cagtggaaac 360
cggcgcgaa aatgcgaagc cttccgcaag ctctttacaa ggaaccctg cttgggtgag 420
ggggcctgga ggtcccgggg aaccacggat gtctgtggcc caatccaagc tgccctggccc 480
gtgggtctta ttacgtcgc atcatgtttg gtgtgggcca tggacaatgt gcacatgcca 540
tggtacgtg gtggaagtca agcgtaaaa cgtgtccaat ggncgtggaag ttggccttcc 600
ttttgacact natggggtg gcctttcttc atggtgngcc caacttacct ttggttggtc 660
ttgncctctg gtgggaatg cttnaattnc agaattttg gggctctgtt tgaagcctgg 720
cttttgcnct taanaacttg anaagttaaa ctcttattaa tccaatggg gttcacctgt 780
aaaggagag gg 792

```

<210> 2

<211> 497

<212> DNA

<213> Mus musculus

<400> 2

```

gtggaaccgg cgcgaagaat gcgaaccttc cgcaagctct ttacaaggaa ccctgcttg 60
gatggtgcca tacaagcctt tgacagcttg cagccatcag ttctgcagga ccagactgct 120
gggtgctgtt tcccgcgggc aaggcacgag tggcctgaga agagctggag gcagaaacag 180

```

```

tccttgtttt gtcctaacgc ccaaggtgtc ctggctgtat gcactcactg ccctggctct 240
ccaggccctg ctctgattag gaacatgaac cgtggacgac acagctgact gccatgtctc 300
ccgatgactg ctactgagc tgaaactccc ttgccctcag gtctgctgcc ctttgcaggc 360
ctggacccct gtgtggctgt cctctggatt gggggctgga ggctaggggc tgactgaaaa 420
gcctgtgttc ccgtcagtag gcatcttgct cattttcttc cccatcctag agctgagcac 480
ccatagatga ggcctca                                     497

```

<210> 3

<211> 901

<212> DNA

<213> Rattus rattus

<400> 3

```

ggcaccgtgg tcacccccaa ctacctggac aacgtgagcg cgcgcgttgc gccctgggtgc 60
ggctgtgagg ccagcggaaa ccggcgcgaa gagtgcgaag ccttccgcaa gctttttaca 120
aggaaccctt gcttgatgg tgccatacaa gcctttgaca gctcgcaacc atcagttctg 180
caggaccagt ggaaccctta ccagaatgct ggggtgctgtt tcctgtgggt gtcctcgatg 240
tccatactca ctgccctggc tctccaggcc ctgctctaata taggaagggtg aaccatggac 300
aacacagctg actgccatgt ctctggatta tgctcactga actgaaactc ccttgccctc 360
aggtctgctg tcctttgcag ttctggaccc ctgcatggct gtctcctgga ctgggagctg 420
gaggctaggg cccgactgtt aggttccctt gttagtaggc atctcgctg ttttcttcac 480
catccttgag atgatggtag atgatattta gcacctgtag acagggcctc attgggcccc 540
ttgggcttac agagcagaac agagactagc ctctgctct tagaattggg tagtgttctt 600
ttccaagaag acatggcact aaggcgatca tatgaacaga ctgacagact gcagtctaaa 660
taccatgcc ccagggccag cgctgacctt gcttgtcacc tatgacatgg cgctgtgtag 720
ggattaaaga gagagattca ggtccctcct gctggacatc ccaactggcct cccagactct 780
cccagcacct gcagtggcac agcagctcaa taaacctatg tgactggaa aaaaaaaaaa 840
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaagaaaa aaaaaaaaaa 900
a                                                    901

```

<210> 4

<211> 872

<212> DNA

<213> Rattus rattus

<400> 4

```

gtatggggag aggatgtgga gttggcagtt tctcatcgtt cccttctgta tttacccttc 60
tcaggcaggc caaggtggag gcctgagtgg cctgagaaga gatggaggca gaaacggtcc 120
cogttttgtc ccaaggtgtc ctcgatgtcc atactcactg ccctggctct ccaggccctg 180
ctctaattag gaaggtgaac catggacaac acagctgact gccatgtctc tggattatgc 240
tactgaact gaaactccct tgccctcagg tetgctgtcc tttgcagttc tggacccctg 300
catggctgtc tcctggactg ggagctggag gctagggccc gactgttagg ttccctgtt 360
agtaggcac tcgcctgttt tcttcacat ccttgagatg atggtagatg atatttagca 420
cctgtagaca gggcctcatt gggccccttg ggcttacaga gcagaacaga gactagcctc 480
ctgctcttag aattgggtag tgttcttttc caagaagaca tggcactaag gcgatcatat 540
gaacagactg acagactgca gtctaaatac ccatgcccc gggccagcgc tgacctgtct 600
tgtcacctat gacatggcgc tgtgtaggga ttaaagagag agattcaggt ccctcctgct 660
ggacatccca ctggcctccc agactctccc agcacctgca gtggcacago agctcaataa 720

```

acccatgtgc actggaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 780
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 840
 aaaaaaaaaa aaaaaagaaa aaaaaaaaaa aa 872

<210> 5

<211> 2522

<212> DNA

<213> Rattus rattus

<400> 5

ctggttaagct ttaaggcaga ggagacctaa gagctgagac atgctatgtt gagtggagcg 60
 tattttacggg tgctgaatga gaggccaggc caggcagttt tatggagtct tggatgccag 120
 agaggtaagg aggtgggaaa ggaagtacta taaacctgaa tttggtgact tggctggatt 180
 tgcatatgtc cagtgccaaag ttcagacata gctgccgggt ttactgatgc tactctccca 240
 aggtcaggca ttctattttc cctgaatgg cttttcatct gtgacttata tacatcttca 300
 ctgaaactac tggtaaactgt ccaggtctgt ctgaggcgga agtcctatgg tctgccatta 360
 agcctcagtg tcctgtcagg tgaagctggg gaggatggaa ggggtccagt agacgctctg 420
 tgatgcatgt gccagttctg gagatggtgg tggaggctga acctgagctt ctgggggaacc 480
 tccgagtact gcctccattc acgacctggg tggatatccc taggacctgc ccatgccgcg 540
 ttctcagga aaaacgggtc acgcctatgg gccacactct ctccccttgg gtttgggtat 600
 ctgccccag ccccgccaa attccgggt gtggaatgtg gagaaccaag cacagaggcg 660
 tgcagcctgc cctcccctca ccagggtcag cgagctccac tgaggggaat cgctgcgtgg 720
 aagcagccga ggcgtgcaca gcagacgagc agtgccagca gctgcgctcc gactacgtgg 780
 cgcaatgcct gggccgggcg ggctggcggg gaccgggag ctgctgcgcg tcccgtgcc 840
 gccgtgccct gcgcgcgttc ttccgccgcg ggccctccggc gctcacgcac gcgctgctct 900
 tctgcggatg cgaaggcccc gcgtgcgccc agcgccggcg ccagacattc gcgcccgcct 960
 gcgcgttctc cgccccccag ctggcgccac cttcctgcct gaagcccttg gaccgctgcg 1020
 agcgaagccg ccggtgccgg tgcgtgcggg gcgggctggg ccgctcaccg gcgtccggcg 1080
 gcgcgcaggc cccgtctctt tgccctccag gcctcatgcg ctcccgcgcg cggtcccgcc 1140
 gacggctgtc cggaggaggg gggcccgcg tgtctgcgcg cctacgcagg ccttgtaggt 1200
 acgctgggcg gcctctggcg ggccgggccc cggaggcaga ttccgggggc ccgtcacagg 1260
 tcctgggggt ccctgcaggc accgtggtca cccccaacta cctggacaac gtgagcgcg 1320
 gcgttgccgc ctggtgcggc tgtgaggcca gcggaaccg gcgcgaagag tgcgaagcct 1380
 tccgcaagct ttttacaagg aaccctgct tgggtgaggg ggctggagag cccgggcaac 1440
 caaggacgtc tatggcccag tctaggtgc ctggcctgtg gggaccctta aatgttttc 1500
 gtcgtgtcgt atttggtgtg ggtgatggac agtgtgcacg tgccatggtg catgggtgga 1560
 agtcagagga caacttgtca gtctctttct accacgtggg tcccgggat agcactgggc 1620
 tcatcagttt tgggtggcaag tgcccttgcc tgctgagcca tcttgctggc tgatgtgagc 1680
 acatttttga tggaaagaaa ctgaggtttc cagagaccag atagccgatc actagagaat 1740
 tcgagagatg tcaagaatct cttagggtta gaaaggatga gttaaaacat gtccaatgac 1800
 ctggagttgg ccaaggctcc ctttggcact actgaggtct tttcctccat gtgttccca 1860
 tttaacgctg ctgttcttgc ctccggatga aatagcgttg ttccagattt ctggggggcc 1920
 ggtttgaagc ctgtctctgc cacttcgtag ccgagagtta aactcttatt aatcctaatt 1980
 gtgttcacct gtaaggcgcg ggtgtgcact tgtcaacctc actcttagca cagtgcctt 2040
 ccatctcagg ccgtgccttg cagattccag ggggtgtctc attttgtctc aagggagtgg 2100
 agctgtttct agggtttccct ggccaaacct tctctggatc tctccactcc atagatggtg 2160
 ccatacaagc ctttgacagc tcgcaacct cagttctgca ggaccagtgg aaccctacc 2220
 agaatgctgg gtgctgtttc ctgtgggtag gtatggggag aggatgtgga gttggcagtt 2280

```

tctcatcggt cccttctgta tttacccttc tcaggcaggc caaggtggag gcctgagtgg 2340
cctgagaaga gatggaggca gaaacggtcc ccgttttgtc ccaaggtgtc ctcgatgtcc 2400
atactcactg ccctggctct ccaggccctg ctctaattag gaaggtgaac catggacaac 2460
acagctgact gccatgtctc tggattatgc tcaactgaact gaaactccct tgcctcagg 2520
tc 2522

```

<210> 6

<211> 953

<212> DNA

<213> Rattus rattus

<400> 6

```

ctggttaagct ttaaggcaga ggagacctaa gagctgagac atgctatggt gagtggagcg 60
tatttacggg tgctgaatga gaggccaggc caggcagttt tatggagtct tggatgccag 120
agagggtcag cgagctccac tgaggggaat cgctgcgtgg aagcagccga ggcgtgcaca 180
gcagacgagc agtgccagca gctgcgtccc gagtacgtgg cgcaatgcct gggccgggcg 240
ggctggcggg gaccggggag ctgcgtgcgc tcccgtgcc gccgtgccct gcgcccgttc 300
ttgccccgag ggcctccggc gctcacgcac gcgctgctct tctgcggatg cgaaggcccc 360
gcgtgcgcgc agcgcgggag ccagacattc gcgcccgcct gcgcttctc cggccccag 420
ctggcgccac ctctctgcct gaagcccttg gaccgctgcg agcgaagccg ccggtgccgg 480
ccccgtctct ttgccttcca ggcctcatgc gctcccgcgc ccggtccccg cgacggctgt 540
ccggaggagg ggggcccgcg gtgtctgcgc gcctacgcag gccttgtagg caccgtggtc 600
acccccaaact acctggacaa cgtgagcgcg cgcttgcggc cctggtgcgg ctgtgaggcc 660
agcggaaacc ggcgcgaaga gtgcgaagcc ttccgcaagc tttttacaag gaaccctgc 720
ttggatggtg ccatacaagc ctttgacagc tcgcaacat cagttctgca ggaccagtgg 780
aaccctacc agaatgctgg gtgctgtttc ctgtgggtgt cctcgatgtc catactcaet 840
gccctggctc tcaggccct gctctaatta ggaaggtgaa ccatggacaa cacagctgac 900
tgccatgtct ctggattatg ctcaactgaac tgaaactccc ttgcctcag gtc 953

```

<210> 7

<211> 1008

<212> DNA

<213> Rattus rattus

<400> 7

```

ctggttaagct ttaaggcaga ggagacctaa gagctgagac atgctatggt gagtggagcg 60
tatttacggg tgctgaatga gaggccaggc caggcagttt tatggagtct tggatgccag 120
agagggtcag cgagctccac tgaggggaat cgctgcgtgg aagcagccga ggcgtgcaca 180
gcagacgagc agtgccagca gctgcgtccc gagtacgtgg cgcaatgcct gggccgggcg 240
ggctggcggg gaccggggag ctgcgtgcgc tcccgtgcc gccgtgccct gcgcccgttc 300
ttgccccgag ggcctccggc gctcacgcac gcgctgctct tctgcggatg cgaaggcccc 360
gcgtgcgcgc agcgcgggag ccagacattc gcgcccgcct gcgcttctc cggccccag 420
ctggcgccac ctctctgcct gaagcccttg gaccgctgcg agcgaagccg ccggtgccgg 480
ccccgtctct ttgccttcca ggcctcatgc gctcccgcgc ccggtccccg cgacggctgt 540
ccggaggagg ggggcccgcg gtgtctgcgc gcctacgcag gccttgtagg caccgtggtc 600
acccccaaact acctggacaa cgtgagcgcg cgcttgcggc cctggtgcgg ctgtgaggcc 660
agcggaaacc ggcgcgaaga gtgcgaagcc ttccgcaagc tttttacaag gaaccctgc 720
ttggatggtg ccatacaagc ctttgacagc tcgcaacat cagttctgca ggaccagtgg 780

```


aaccctacc agaatgctgg gcaggccaag gtggaggcct gaggggcctg agaagagatg 840
 gaggcagaaa cgggtccccgt tttgtcccaa ggtgtcctcg atgtccatac tcaactgccct 900
 ggctctccag gccctgctct aattaggaag gtgaaccatg gacaacacag ctgactgcca 960
 tgtctctgga ttatgctcac tgaactgaaa ctcccttgcc ctcagggtc 1008

<210> 8

<211> 273

<212> PRT

<213> Rattus rattus

<400> 8

Met Leu Ser Gly Ala Tyr Leu Arg Val Leu Asn Glu Arg Pro Gly Gln
 1 5 10 15

Ala Val Leu Trp Ser Leu Gly Cys Gln Arg Gly Ser Ala Ser Ser Thr
 20 25 30

Glu Gly Asn Arg Cys Val Glu Ala Ala Glu Ala Cys Thr Ala Asp Glu
 35 40 45

Gln Cys Gln Gln Leu Arg Ser Glu Tyr Val Ala Gln Cys Leu Gly Arg
 50 55 60

Ala Gly Trp Arg Gly Pro Gly Ser Cys Val Arg Ser Arg Cys Arg Arg
 65 70 75 80

Ala Leu Arg Arg Phe Phe Ala Arg Gly Pro Pro Ala Leu Thr His Ala
 85 90 95

Leu Leu Phe Cys Gly Cys Glu Gly Pro Ala Cys Ala Glu Arg Arg Arg
 100 105 110

Gln Thr Phe Ala Pro Ala Cys Ala Phe Ser Gly Pro Gln Leu Ala Pro
 115 120 125

Pro Ser Cys Leu Lys Pro Leu Asp Arg Cys Glu Arg Ser Arg Arg Cys
 130 135 140

Arg Pro Arg Leu Phe Ala Phe Gln Ala Ser Cys Ala Pro Ala Pro Gly
 145 150 155 160

Ser Arg Asp Gly Cys Pro Glu Glu Gly Gly Pro Arg Cys Leu Arg Ala
 165 170 175

Tyr Ala Gly Leu Val Gly Thr Val Val Thr Pro Asn Tyr Leu Asp Asn
 180 185 190

Val Ser Ala Arg Val Ala Pro Trp Cys Gly Cys Glu Ala Ser Gly Asn

195 200 205
 Arg Arg Glu Glu Cys Glu Ala Phe Arg Lys Leu Phe Thr Arg Asn Pro
 210 215 220
 Cys Leu Asp Gly Ala Ile Gln Ala Phe Asp Ser Ser Gln Pro Ser Val
 225 230 235 240
 Leu Gln Asp Gln Trp Asn Pro Tyr Gln Asn Ala Gly Cys Cys Phe Leu
 245 250 255
 Trp Val Ser Ser Met Ser Ile Leu Thr Ala Leu Ala Leu Gln Ala Leu
 260 265 270
 Leu

<210> 9
 <211> 258
 <212> PRT
 <213> Rattus rattus

<400> 9
 Met Leu Ser Gly Ala Tyr Leu Arg Val Leu Asn Glu Arg Pro Gly Gln
 1 5 10 15
 Ala Val Leu Trp Ser Leu Gly Cys Gln Arg Gly Ser Ala Ser Ser Thr
 20 25 30
 Glu Gly Asn Arg Cys Val Glu Ala Ala Glu Ala Cys Thr Ala Asp Glu
 35 40 45
 Gln Cys Gln Gln Leu Arg Ser Glu Tyr Val Ala Gln Cys Leu Gly Arg
 50 55 60
 Ala Gly Trp Arg Gly Pro Gly Ser Cys Val Arg Ser Arg Cys Arg Arg
 65 70 75 80
 Ala Leu Arg Arg Phe Phe Ala Arg Gly Pro Pro Ala Leu Thr His Ala
 85 90 95
 Leu Leu Phe Cys Gly Cys Glu Gly Pro Ala Cys Ala Glu Arg Arg Arg
 100 105 110
 Gln Thr Phe Ala Pro Ala Cys Ala Phe Ser Gly Pro Gln Leu Ala Pro
 115 120 125

Pro Ser Cys Leu Lys Pro Leu Asp Arg Cys Glu Arg Ser Arg Arg Cys
 130 135 140

Arg Pro Arg Leu Phe Ala Phe Gln Ala Ser Cys Ala Pro Ala Pro Gly
 145 150 155 160

Ser Arg Asp Gly Cys Pro Glu Glu Gly Gly Pro Arg Cys Leu Arg Ala
 165 170 175

Tyr Ala Gly Leu Val Gly Thr Val Val Thr Pro Asn Tyr Leu Asp Asn
 180 185 190

Val Ser Ala Arg Val Ala Pro Trp Cys Gly Cys Glu Ala Ser Gly Asn
 195 200 205

Arg Arg Glu Glu Cys Glu Ala Phe Arg Lys Leu Phe Thr Arg Asn Pro
 210 215 220

Cys Leu Asp Gly Ala Ile Gln Ala Phe Asp Ser Ser Gln Pro Ser Val
 225 230 235 240

Leu Gln Asp Gln Trp Asn Pro Tyr Gln Asn Ala Gly Gln Ala Lys Val
 245 250 255

Glu Ala

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/04918

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/11 C12N15/12 C07K14/71 C12Q1/68 A61K38/17
A61K48/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, STRAND, EMBL, MEDLINE, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THOMPSON J ET AL.: "GFRalpha-4, a new GDNF family receptor" MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 11, no. 3, June 1998 (1998-06), pages 117-126, XP000960388 cited in the application	1,3-5, 7-21,36
Y	the whole document	22,23, 26-29, 37-40, 43-46



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

17 November 2000

Date of mailing of the international search report

04/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van de Kamp, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 00/04918

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ENOKIDO Y ET AL.: "GFRalpha-4 and the tyrosine kinase Ret form a receptor complex for persephin" CURRENT BIOLOGY, vol. 8, no. 18, 10 September 1998 (1998-09-10), pages 1019-1022, XP000960386 cited in the application the whole document page 1019, right-hand column, line 12-14</p>	<p>1,3-5, 7-17,21, 24-35, 38-44,46</p>
X	<p>DATABASE EMBL 'Online! EMBL; ID AU035938, AC AU035938, 8 October 1998 (1998-10-08) HASHIMOTO K ET AL.: "Mus musculus brain cDNA, clone MNCb-1073 : 5' end" XP002152925 cited in the application the whole document</p>	<p>1-5, 7-19,21, 36</p>
X	<p>DATABASE EMBL 'Online! EMBL; ID AA823200, AC AA823200, 18 February 1998 (1998-02-18) MARRA M ET AL.: "vw41h08.r1 Soares mouse mammary gland NbMMG Mus musculus cDNA clone IMAGE:1246431 5', mRNA sequence" XP002152926 cited in the application the whole document</p>	<p>1-5, 7-19,21, 36</p>
X	<p>WO 99 14235 A (MILBRANDT JEFFREY D ;DESAUVAGE FRED (US); KLEIN ROBERT (US); UNIV) 25 March 1999 (1999-03-25) the whole document</p>	<p>24,25, 31-35, 41,42</p>
Y	<p>WO 97 33912 A (GENENTECH INC ;RYAN ANNE M (US); KLEIN ROBERT D (US); MOORE MARK W) 18 September 1997 (1997-09-18) the whole document</p>	<p>22,23, 26-29, 37-40, 43-46</p>
A	<p>AIRAKSINEN M S ET AL.: "GDNF family neurotrophic factor signaling: four masters, one servant?" MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 13, no. 5, May 1999 (1999-05), pages 313-325, XP000960431 cited in the application the whole document page 321, right-hand column, line 33-36 figures 1,2</p>	<p>1-46</p>

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 00/04918

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SAARMA M ET AL.: "Other neurotrophic factors: Glial cell line-derived neurotrophic factor (GDNF)" MICROSCOPY RESEARCH AND TECHNIQUE, vol. 45, no. 4-5, 1 June 1999 (1999-06-01), pages 292-302, XP000960924 abstract page 294, right-hand column, line 57-61 figure 2 ---	1-46
P,X	WO 99 50298 A (MILLENNIUM PHARMACEUTICALS INC) 7 October 1999 (1999-10-07) the whole document ---	1-5, 7-23, 26-30, 36-40, 43-46
P,X	DATABASE EMBL 'Online! EMBL; ID AF155960, AC AF155960, 28 July 1999 (1999-07-28) GUNN T M ET AL.: "Mus musculus recombination breakpoint containing region" XP002152927 cited in the application the whole document	1-5,7,8, 21
X	-& GUNN T M ET AL.: "The mouse mahogany locus encodes a transmembrane form of human attractin" NATURE, vol. 398, no. 6723, 11 March 1999 (1999-03-11), pages 152-156, XP002152923	1-5, 7-21,36
Y	page 153, right-hand column, line 11-14	22,23, 26-29, 37-40, 43-46
P,X	WO 00 05373 A (MILLENNIUM PHARMACEUTICALS INC) 3 February 2000 (2000-02-03) page 87, line 30 -page 88, line 17 figure 3A figure 3D --- -/--	1-5,7,8, 21

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/04918

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE EMBL 'Online! EMBL; ID AW528607, AC AW528607, 8 March 2000 (2000-03-08) SOARES M B: "UI-R-B01-ajr-c-09-0-UI.sr UI-R-B01 Rattus norvegicus cDNA clone, UI-R-B01-ajr-c-09-0-UI 3', mRNA sequence" XP002153002 the whole document</p>	1-5,7,8, 21
X	<p>-& BONALDO M F ET AL.: "Normalization and subtraction: two approaches to facilitate gene discovery" GENOME RESEARCH, vol. 6, no. 9, September 1996 (1996-09), pages 791-806, XP002039972 abstract</p>	1-5,7
P,X	<p>--- DATABASE EMBL 'Online! EMBL; ID MMU276872, AC AJ276872, 1 May 2000 (2000-05-01) AIRAKSINEN M S: "Mus musculus mRNA for GDNF family receptor alpha 4, putative secreted isoform (Gfra4 gene)" XP002152928 the whole document</p>	1-5,7,8, 21
T	<p>-& LINDAHL M ET AL.: "Expression and alternative splicing of mouse Gfra4 suggest roles in endocrine cell development" MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 15, no. 6, June 2000 (2000-06), pages 522-533, XP000960392 the whole document</p>	1-5,7,8, 18,19,21
T	<p>--- MASURE S ET AL.: "Mammalian GFRA-4, a divergent member of the GFRA family of coreceptors for GDNF family ligands, is a receptor for the neurotrophic factor persephin" JOURNAL BIOLOGICAL CHEMISTRY (JBC PAPERS IN PRESS), 24 August 2000 (2000-08-24), XP002152924 Published as Manuscript M003867200 the whole document</p>	1-46
T	<p>--- DATABASE EMBLNEW 'Online! EMBL; ID AF253318, AC AF253318, 26 October 2000 (2000-10-26) ZHOU B ET AL.: "Homo sapiens GFR receptor alpha 4 protein (GFRA4) mRNA, complete cds" XP002152929 the whole document</p>	1-5,7,8, 21

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-5,7-46 (all partially); 6 (completely)

A nucleic acid according to SEQ ID NOs 5, 6 or 7 encoding a rat GDNF family receptor alpha-4 (rGFRalpha-4) according to SEQ ID NOs 8 or 9 or encoding a functional equivalent, and said encoded GFRalpha-4 proteins. Hybridizing nucleic acid molecules, vectors, hosts, transgenic cells, tissues or organisms, and pharmaceutical compositions. Agonists, antagonists and ligands, methods for their identification and use thereof. Antibodies and their use. Kits.

2. Claims: 1-5,7-46 (all partially)

A nucleic acid encoding a mouse GDNF family receptor alpha-4 (mGFRalpha-4) which is a functional equivalent of the receptor encoded by SEQ ID NOs 8 or 9, and said encoded mGFRalpha-4 protein. Hybridizing nucleic acid molecules, vectors, hosts, transgenic cells, tissues or organisms, and pharmaceutical compositions. Agonists, antagonists and ligands, methods for their identification and use thereof. Antibodies and their use. Kits.

3. Claims: 1-5,7-46 (all partially)

A nucleic acid encoding a human GDNF family receptor alpha-4 (hGFRalpha-4) which is a functional equivalent of the receptor encoded by SEQ ID NOs 8 or 9, and said encoded hGFRalpha-4 protein. Hybridizing nucleic acid molecules, vectors, hosts, transgenic cells, tissues or organisms, and pharmaceutical compositions. Agonists, antagonists and ligands, methods for their identification and use thereof. Antibodies and their use. Kits.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 24, 25, 31-35

Remark (2): Claims 24, 25, and 31-35 refer to agonists and/or antagonists of the polypeptide(s) without giving a true technical characterisation. Moreover, no specific compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/04918

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9914235 A	25-03-1999	AU 9483898 A EP 1009768 A	05-04-1999 21-06-2000
WO 9733912 A	18-09-1997	AU 719482 B AU 2217297 A CA 2246768 A EP 0888385 A ZA 9702235 A	11-05-2000 01-10-1997 18-09-1997 07-01-1999 14-09-1998
WO 9950298 A	07-10-1999	AU 3206899 A	18-10-1999
WO 0005373 A	03-02-2000	AU 5118399 A	14-02-2000